2026 INTERIM REPORT
中期報告

RICI HEALTHCARE HOLDINGS LIMITED
瑞慈醫療服務控股有限公司

CONTENTS

Definitions

In this interim report, unless the context otherwise requires, the following expressions shall have the following meanings.

"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	our board of Directors
"BVI"	British Virgin Islands
"CG Code"	the "Corporate Governance Code" as contained in Appendix C1 to the Listing Rules
"Chelsea Grace"	Chelsea Grace Holdings Limited (翠慈控股有限公司), a company incorporated in the BVI with limited liability on July 11, 2014, which is wholly owned by Dr. Mei
"China" or "PRC"	the People's Republic of China, which, for the purpose of this interim report and for geographical reference only, excludes Hong Kong, Macau and Taiwan
"Class III Hospital"	the largest and best regional hospitals in China designated as Class III hospitals by the NHC's hospital classification system, typically having more than 500 beds, providing high-quality professional healthcare services covering a wide geographic area and undertaking more sophisticated academic and scientific research initiatives
"Company", "our Company", "Rici", "Group", "we", "our" or "us"	Rici Healthcare Holdings Limited (瑞慈醫療服務控股有限公司), a company incorporated under the laws of the Cayman Islands with limited liability on July 11, 2014 and except where the context indicated otherwise, (i) our subsidiaries and (ii) with respect to the period before our Company became the holding company of our present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)
"Company Secretary"	the secretary of the Company
"Controlling Shareholder(s)"	Dr. Mei and Chelsea Grace or any one of them
"Director(s)"	the director(s) of our Company or any one of them
"Dr. Fang"	Dr. Fang Yixin, our chairman, chief executive officer, executive Director, the spouse of Dr. Mei and the father of Mr. Fang Haoze
"Dr. Mei"	Dr. Mei Hong, our executive Director, a Controlling Shareholder, the spouse of Dr. Fang and the mother of Mr. Fang Haoze

"Grade A, Grade B and Grade C"	hospitals in China can be categorized into Class I, II and III in terms of service quality, management level, medical equipment, hospital size and medical technology. Each class can be further divided into Grade A, Grade B and Grade C. Class III Grade A hospitals are the top level hospitals in China
"HK$" or "Hong Kong dollars"	Hong Kong dollars and cents, each being the lawful currency of Hong Kong
"HKFRSs"	Hong Kong Financial Reporting Standards
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"IPO"	the initial public offering of the Company, having become unconditional in all aspects on October 6, 2016
"Listing"	the listing of the Shares on the Main Board of the Stock Exchange
"Listing Date"	October 6, 2016, on which the Shares were listed and from which dealings therein were permitted to take place on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)
"Model Code"	the "Model Code for Securities Transactions by Directors of Listed Issuers" set out in Appendix C3 to the Listing Rules
"Nantong Rich Hospital"	Nantong Rich Hospital Co., Ltd. (南通瑞慈醫院有限公司), a company incorporated in the PRC with limited liability on August 14, 2000, which is an indirectly wholly-owned subsidiary of our Company
"Nantong Rich Meidi Elderly Care Centre"	Nantong Rich Meidi Elderly Care Centre Co., Ltd. (南通瑞慈美邸護理院有限公司), a company incorporated in the PRC with limited liability on August 19, 2014, which is a non-wholly-owned subsidiary of our Group
"NHC"	National Health Commission (國家衛生健康委員會) of the PRC
"Nomination Committee"	the nomination committee of the Board
"Pre-IPO Share Option Scheme"	the pre-IPO share option scheme adopted by the Company on September 19, 2016
"Prospectus"	the prospectus of the Company dated September 26, 2016
"Remuneration Committee"	the remuneration committee of the Board
"Reporting Period"	the six months ended June 30, 2026

Definitions

"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	ordinary share(s) of US$0.0001 each in the issued share capital of the Company
"Shareholder(s)"	holder(s) of Shares
"Share Option Scheme"	the share option scheme conditionally adopted by the Company on September 19, 2016
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"%"	per cent

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Dr. Fang Yixin *(Chairman and Chief Executive Officer)*
Dr. Mei Hong
Mr. Fang Haoze
Ms. Lin Xiaoying

Independent Non-executive Directors

Ms. Wong Sze Wing
Mr. Jiang Peixing
Mr. Tian Wenguo

COMPANY SECRETARY

Mr. Chen Kun *(Solicitor of HKSAR)*
(resigned on March 26, 2026)
Ms. Lee Hang Siu *(appointed on March 26, 2026)*

AUTHORISED REPRESENTATIVES

Dr. Fang Yixin
Mr. Chen Kun *(resigned on March 26, 2026)*
Ms. Lee Hang Siu *(appointed on March 26, 2026)*

AUDIT COMMITTEE

Ms. Wong Sze Wing *(Chairlady)*
Mr. Jiang Peixing
Mr. Tian Wenguo

REMUNERATION COMMITTEE

Mr. Jiang Peixing *(Chairman)*
Ms. Wong Sze Wing
Dr. Mei Hong

NOMINATION COMMITTEE

Dr. Fang Yixin *(Chairman)*
Mr. Jiang Peixing
Ms. Wong Sze Wing

REGISTERED OFFICE

4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

17/F
Qiantan International Plaza
No. 90 Qirong Road
Pudong New District
Shanghai
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 504, 5/F,
Cheong Tai Commercial Building,
60–66 Wing Lok Street,
Sheung Wan,
Hong Kong

PRINCIPAL BANKERS

Standard Chartered Bank (Hong Kong) Limited
Room 1505, 15/F,
New World Tower 1,
No. 16, Queen's Road Central,
Central
Hong Kong

Shanghai Pudong Development Bank
Zhangjiang Innovation Sub-branch
Building D, No. 56, Boyun Road
Pudong New District
Shanghai
PRC

China Merchants Bank
Jinshajiang Road Branch
1759 Jinshajiang Road
Putuo District
Shanghai
PRC

Bank of Communications
Zhang Jiang Sub-branch
560 Songtao Road
Pudong New District
Shanghai
PRC

Bank of Shanghai
Zhangjiang Sub-Branch
Room 301, Tower G2,
Zhangjiang National Innovation Center Phase 1,
No. 999, Dangui Road,
Pudong New District
Shanghai
PRC

HONG KONG LEGAL ADVISER

Jun He Law Offices
7/F, AIA Central,
1 Connaught Road Central,
Central, Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Ascentium (Cayman) Limited
(formerly known as Harneys Services (Cayman) Limited)
4th Floor, Harbour Place
103 South Church Street
P.O. Box 10240
Grand Cayman KY1-1002
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR

Computershare Hong Kong Investor Services Limited
Shops 1712–1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wanchai
Hong Kong

STOCK CODE AND BOARD LOT

Stock Code: 1526
Board Lot: 1,000

WEBSITE

www.rich-healthcare.com

Management Discussion and Analysis

BUSINESS OVERVIEW AND STRATEGIC OUTLOOK

Industry Overview

In 2026, China's healthcare industry has entered a new stage of high-quality development led by new quality productive forces. Jointly driven by deepening medical reform policies and artificial intelligence ("**AI**") technology, it is exhibiting three major trends, namely, innovative breakthroughs, balanced development, and value reshaping. At the policy level, the government has continued to deepen reforms in hierarchical diagnosis and treatment and medical service pricing, promoting the allocation of high-quality medical resources to lower-level areas and ensuring balanced regional distribution. Through a new round of dynamic adjustments to the medical insurance catalog and the deepening of centralized procurement for drugs and medical devices, it has further unlocked the value of clinical innovation and delivered benefits to the public. At the technology level, large models have been deeply integrated into the entire healthcare process. AI-assisted diagnostics, intelligent comprehensive health management, and high-precision surgical robots have achieved large-scale commercialization. According to data from the NHC, in 2025, the number of patient visits to primary medical and health institutions nationwide increased by 52.6% to reach 5.56 billion, demonstrating the continued effectiveness of the hierarchical diagnosis and treatment system. On the demand side, in the face of a deepening aging population and an upgrade in proactive health awareness across the entire population, the demand for multi-level, personalized precision medicine has surged, creating strong development momentum for the entire industry chain.

Driven by the dual forces of policy guidance and technological empowerment, the hospital sector is being compelled to shift from extensive expansion to a new track of refined and high-quality operations. Under the assurance of regularized medical compliance supervision, the industry's diagnosis and treatment ecosystem has become more transparent and clear, leading to the sustained release of demand for both essential medical treatment and high-end consumer healthcare. According to the latest data from the NHC, from January to November 2025, the total number of patient visits to medical institutions nationwide reached 7.10 billion, representing a year-on-year increase of 3.3%. Of these, hospitals accounted for 4.24 billion visits, a year-on-year increase of 3.4%, with both public and private hospitals maintaining a steady growth trend.

For the medical examination industry, with the growing prevalence of the concepts of "early screening and early diagnosis" and preventive medicine, the medical examination market has continued to expand steadily. With the increase in residents' disposable income and a stronger willingness to invest in health, the demand for in-depth specialized screenings and high-end personalized medical examination services has been further unleashed. According to data from industry research institutions, the market size of China's medical examination industry surpassed RMB370 billion in 2025, with the increase in average spending per customer and the addition of specialized testing items becoming the core engines driving growth. Moreover, the application of cutting-edge technologies such as AI-powered image screening, AI-assisted diagnosis, and AI quality control has significantly improved the precision and operational efficiency of medical examination services. This has not only given rise to innovative services such as early warnings for multiple diseases, but also accelerated the efficient linkage of the industry chain, including medical examinations with precision medicine, specialized disease management, and health insurance, driving the industry's leap towards a high-value ecosystem.

General hospital business

Nantong Rich Hospital is a large-scale general hospital integrating medical treatment, education and research. As one of the regional medical centers in Nantong, it is currently a Class III Grade B general hospital, a designated hospital for medical insurance reimbursement and a national standardized medical residency training coordination base.

On June 14, 2025, Shanghai East Hospital (East Hospital Affiliated to Tongji University) (上海市東方醫院(同濟大學附屬東方醫院)), the Nantong Economic and Technological Development Area (南通市經濟技術開發區), and Nantong Rich Hospital formally signed a strategic cooperation agreement, and on the same day inaugurated "Shanghai East Hospital Nantong Rich Hospital (上海市東方醫院南通瑞慈醫院)". On January 28, 2026, the three parties further signed an agreement to deepen their strategic cooperation, advancing the Shanghai-Nantong medical collaboration into its 2.0 phase. Shanghai East Hospital provides comprehensive management, exporting its top-tier medical technology, management models, and brand resources to Nantong Rich Hospital. During the Reporting Period, Nantong Rich Hospital, in collaboration with Shanghai East Hospital, established four benchmark centers: the Cardiovascular Center, Cerebrovascular Center, Oncology Center, and the East Rich Gallstone Center (東方瑞慈膽石中心); launched two national-level renowned doctor studios; and filled several gaps in complex local surgical procedures. In addition, the Spine Surgery Department was awarded the global "Gold Standard" certification by the International Osteoporosis Foundation (IOF).

During the Reporting Period, Nantong Rich Hospital provided services for 144,924 outpatient and emergency visits (same period in 2025: 142,777) and 11,975 inpatient visits (same period in 2025: 12,456), representing a year-on-year increase of 1.50% and a year-on-year decrease of 3.86%, respectively. Nantong Rich Hospital focused on tackling difficult Level III and IV surgeries, performing 1,918 such surgeries in the first half of the year, a year-on-year increase of 18.7%, and introduced over 30 new technologies in complex minimally invasive procedures, intracardiac interventions, radical tumor resections, and joint replacements. Its capabilities in treating acute, critical, and severe cases were significantly enhanced. The three major centers for chest pain, stroke, and trauma operated efficiently, with the volume of patients treated after being transported by "120" emergency services increasing by 8% year-on-year, and the inpatient conversion rate rising by 10%.

Located in Nantong Rich Hospital, Nantong Rich Meidi Elderly Care Centre is a joint venture formed by Nantong Rich Hospital and Medical Care Service Company Inc., which is a senior care institution combined with medical and wellness services integrating professional senior care, nursing care, and rehabilitation and physical therapy. As of June 30, 2026, the nursing home had 103 elderly residents (as of June 30, 2025: 89), with the occupancy rate increasing to 97.2% (as of June 30, 2025: 84.0%). The specialized rehabilitation hospital has completed its preparatory work and entered the acceptance phase, and is expected to officially commence operations in the near future. The implementation of the Group's integrated strategy for medical care, rehabilitation, and elderly care is accelerating, and a closed-loop, full-lifecycle health service system is beginning to take shape.

Medical examination business

The medical examination business is the core pillar of our Group's revenue. During the Reporting Period, the Group deepened its dual-brand strategic layout for "RICI HEALTH CHECKUP" and "XMEDIC", relying on differentiated positioning to precisely meet stratified health consumption demands. Among them, "RICI HEALTH CHECKUP" focuses on the mid-to-high-end mass and corporate markets, while "XMEDIC" concentrates on high-end members and precision screening markets The segment adheres to a key market strategy, steadily consolidating its presence in areas with high concentrations of high-net-worth customers, such as the Yangtze River Delta, Beijing, and the Greater Bay Area, while simultaneously expanding into new first-tier and key cities. As of June 30, 2026, the Group had 80 medical examination centers in operation nationwide, covering 28 cities.

In terms of brand communication, following the title sponsorship of the Jiangsu Football City League (Jiangsu Super League) in 2025, Rici Healthcare further deepened its cooperation in 2026, becoming the "Official Event Partner and Designated Medical Service Provider for the 2026 Jiangsu Super League Nantong Division". Through various initiatives such as pre-and post-match rehabilitation support, a green channel for medical services for fans, and health education for spectators, it integrated health concepts into the public sports scene, comprehensively safeguarding the health of players and fans, and achieving a leap in high-quality brand influence.

The Group's medical examination business has always adhered to the pursuit of medical quality and high-quality services, and has been continuously committed to improving customer experience. During the Reporting Period, the Group continued to increase its investment in hardware and empowerment through cutting-edge equipment, adding 64 ultrasound units and 8 magnetic resonance imaging (MRI) machines, further strengthening the hardware support for precision screening. At the same time, during the Reporting Period, the Group comprehensively promoted the standardization of medical quality, service standardization, and digital and intelligent construction. In terms of medical quality and safety management, 4 special committees were formed and the "Tiered Standards for Critical Abnormal Findings (2026 Edition)" were revised. In the first half of 2026, the detection rate of critical abnormal findings among medical examination clients reached 9.59%, with the secondary follow-up rates for critical abnormal findings for "RICI HEALTH CHECKUP" and "XMEDIC" reaching 86.58% and 90.63%, respectively. In terms of customer service, the five-star rating for on-site services for "RICI HEALTH CHECKUP" and "XMEDIC" reached 98.35% and 99.68%, respectively. In terms of digital and intelligent empowerment, five major AI applications were implemented: AI-powered primary review, AI customer service, AI contract audit, AI group health report generation, and AI report translation. Among these, AI-powered primary review has been rolled out to all institutions nationwide, with an adoption rate of 85% for pre-generated reports, significantly enhancing operational efficiency and the level of refined services.

Outlook

The year 2026 marks a crucial starting point for the full implementation of the national "15th Five-Year" Health Plan, opening a new strategic window for the leapfrog development of the comprehensive health industry. Rici Healthcare is anchored to the grand blueprint of "Healthy China 2030" and actively responds to the national top-level design to "strengthen comprehensive prevention and control of chronic diseases and develop end-to-end services covering prevention, treatment, rehabilitation, and health management". It puts the scientific concept of "early screening, early diagnosis, and early treatment" into practice, deeply contributing to the national vision of "increasing average life expectancy by one year by 2030". Looking ahead, the Group will fully embark on a transformation and upgrade towards becoming a "technology-driven medical service group". Closely following the mid-to-long-term strategic plan of "high-quality development, cost reduction and efficiency improvement, upholding fundamental principles and innovating, and seeking progress while maintaining stability", it will comprehensively promote the steady progress of all its businesses.

In terms of general hospital and elderly care businesses, Nantong Rich Hospital will focus on "achieving Class III Grade A hospital status" as a key initiative. It will continue to deepen its cooperation with Shanghai East Hospital in specialized department development, recruitment of renowned doctors, and scientific research and training, so as to continuously increase the proportion of difficult Level III and IV surgeries and enhance its core competitiveness. It will accelerate the "one body, two wings" layout to build a comprehensive medical care, rehabilitation, and elderly care complex with a benchmark effect in the Yangtze River Delta. At the same time, it will strengthen medical insurance compliance and value creation, further promote role-based responsibility and new performance reforms, and fully stimulate internal organizational vitality.

In terms of medical examination business, the Group will, on the basis of consolidating its existing competitive advantages, continue to implement a synergistic dual-brand strategy with "RICI HEALTH CHECKUP" and "XMEDIC" to meet the diverse and personalized health management needs of consumers. As an advocate and practitioner of scientific medical examination standards, the Group will actively explore upgrading its service model from simple health check-ups to full-cycle health management. At the same time, the Group will fully leverage the precision advantages of its high-end medical equipment, accelerate the deep integration of cutting-edge technologies such as AI with the entire medical service process, and continuously enhance its precision screening capabilities, institutional operational efficiency, and customer service level.

FINANCIAL REVIEW

Revenue

The Group's revenue was mainly generated from general hospital business and medical examination business. The following table sets forth the components of our revenue by operating segments for the periods indicated:

	Six months ended June 30,		
	2026	2025	Percentage change
	RMB'000	RMB'000	
General hospital business	**219,362**	234,004	(6.3%)
Medical examination business	**927,552**	925,129	0.3%
Inter-segment	**(8,336)**	(14,284)	(41.6%)
Total	**1,138,578**	1,144,849	(0.5%)

The Group's revenue for the Reporting Period amounted to RMB1,138.6 million, representing a decrease of 0.5% as compared to that of RMB1,144.8 million for the corresponding period in 2025. The year-on-year decrease in revenue during the Reporting Period was mainly attributable to the impact of external competitive pressure on the general hospital business, resulting in a decline in revenue.

Revenue from the general hospital business for the Reporting Period amounted to RMB211.0 million, representing a decrease of 4.0% from that of RMB219.7 million for the corresponding period in 2025, excluding inter-segment revenue of RMB8.3 million and RMB14.3 million for the six months ended June 30, 2026 and 2025, respectively. The decrease in revenue from the general hospital business was mainly due to the impact of external competition, as major public hospitals in the region continued to expand, diverting a portion of patients and resulting in a year-on-year decline in revenue.

Revenue from the medical examination business for the Reporting Period amounted to RMB927.6 million, representing an increase of 0.3% from that of RMB925.1 million for the corresponding period in 2025. The growth was mainly attributable to the increase in revenue from the "XMEDIC" brand, a high-end medical examination business line, as compared to the corresponding period of last year.

Cost of Sales

The Group's cost of sales primarily consists of pharmaceuticals and medical consumables costs, staff costs and depreciation and amortization expenses. The following table sets forth an analysis of cost of sales by operating segments for the periods indicated:

	Six months ended June 30,		Percentage
	2026	2025	change
	RMB'000	RMB'000	
General hospital business	**184,752**	201,037	(8.1%)
Medical examination business	**565,059**	550,506	2.6%
Inter-segment	**(8,336)**	(14,284)	(41.6%)
Total	**741,475**	737,259	0.6%

The Group's cost of sales for the Reporting Period amounted to RMB741.5 million, representing an increase of 0.6% from that of RMB737.3 million for the corresponding period in 2025.

Cost of sales from the general hospital business for the Reporting Period amounted to RMB184.8 million, representing a decrease of 8.1% from that of RMB201.0 million for the corresponding period in 2025. The decrease in cost of sales of the general hospital business during the Reporting Period was mainly due to the decrease in revenue of the general hospital business during the Reporting Period.

Cost of sales from the medical examination business for the Reporting Period amounted to RMB565.1 million, representing an increase of 2.6% from that of RMB550.5 million for the corresponding period in 2025. The increase in cost of sales of the medical examination business during the Reporting Period was mainly due to the increase in its revenue.

Gross Profit

The Group's gross profit decreased from RMB407.6 million for the six months ended June 30, 2025 to RMB397.1 million for the Reporting Period. Gross profit margin decreased by 0.7 percentage points from 35.6% for the six months ended June 30, 2025 to 34.9% for the Reporting Period.

Distribution Costs and Selling Expenses

The Group's distribution costs and selling expenses for the Reporting Period amounted to RMB190.3 million, as compared to RMB134.5 million for the corresponding period in 2025. The increase was mainly because the Company built up its sales talent pool for the medical examination business, leading to a corresponding increase in staff costs and an increase in promotional expenses.

Administrative Expenses

The Group's administrative expenses for the Reporting Period amounted to RMB105.8 million, representing a decrease as compared to that of RMB116.7 million for the corresponding period in 2025.

Other Income

The Group's other income, which is mainly comprised of government subsidies, amounted to RMB23.2 million during the Reporting Period (corresponding period in 2025: RMB21.0 million).

Other Losses

The Group's other losses for the Reporting Period amounted to RMB0.1 million, as compared to that of RMB5.9 million for the corresponding period in 2025. Other losses during the Reporting Period were mainly represented by losses on disposal of equipment and other miscellaneous losses.

Finance Costs — Net

Our finance costs — net amounted to RMB43.9 million during the Reporting Period, as compared to that of RMB50.1 million for the corresponding period in 2025. This was primarily due to interest expenses of approximately RMB42.5 million, exchange losses of approximately RMB2.3 million, and interest income of RMB1.0 million incurred during the Reporting Period.

Share of Results of Investments Accounted for Using Equity Method

For the Reporting Period, the Group recognised a share of loss of RMB0.3 million from investments accounted for using equity method (corresponding period in 2025: share of profit of RMB0.6 million) in its consolidated results.

Income Tax Expense

For the Reporting Period, income tax expense amounted to RMB23.1 million (corresponding period in 2025: income tax expense of RMB39.7 million).

Profit for the Period

As a result of the above, the Group reported a net profit of RMB65.1 million for the Reporting Period (corresponding period in 2025: a net profit of RMB79.7 million).

Adjusted EBITDA

To supplement our interim condensed consolidated financial information which are presented in accordance with HKAS 34 Interim Financial Reporting, we use adjusted EBITDA as an additional financial measure. We define adjusted EBITDA as profit for the period before certain expenses and depreciation and amortization as set out in the table below. Adjusted EBITDA is not an alternative to (i) profit before income tax or profit for the period (as determined in accordance with HKFRSs) as a measure of our operating performance; (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs; or (iii) any other measures of performance or liquidity. The following table reconciles our profit for the periods under HKFRSs to our definition of adjusted EBITDA for the periods indicated.

	Six months ended June 30,	
	2026	2025
	RMB'000	RMB'000
Calculation of adjusted EBITDA		
Profit for the Period	**65,136**	79,745
Adjustments to the following items:		
Income tax expense	**23,143**	39,696
Finance costs — net	**43,863**	50,086
Depreciation and amortization	**204,006**	211,436
Pre-opening expenses and EBITDA loss of soft-opening[1]	**3,749**	5,636
Adjusted EBITDA	**339,897**	386,599
Adjusted EBITDA margin[2]	**29.9%**	33.8%

Notes:

(1) Primarily represents (a) the pre-opening expenses, such as staff costs and rental expenses, incurred in the applicable period in connection with the construction of medical examination centers; and (b) the EBITDA loss incurred during the period when the newly opened medical examination centers commenced their operations.

(2) The calculation of adjusted EBITDA margin is based on adjusted EBITDA divided by revenue and multiplied by 100%.

The adjusted EBITDA amounted to RMB339.9 million during the Reporting Period, representing a decrease of 12.1% as compared to that of RMB386.6 million for the corresponding period in 2025, mainly due to the decrease in revenue from the general hospital business, resulting in a decrease in profit.

FINANCIAL POSITION

Property and Equipment

Property and equipment primarily consist of buildings, medical equipment, general equipment, leasehold improvements and construction in progress. As at June 30, 2026, the property and equipment of the Group amounted to RMB1,379.9 million, representing a decrease of RMB42.9 million as compared to that of RMB1,422.8 million as at December 31, 2025.

Trade Receivables

As at June 30, 2026, the trade receivables of the Group amounted to RMB247.4 million, representing a decrease of RMB38.7 million as compared to RMB286.1 million as at December 31, 2025.

Net Current Liabilities

As at June 30, 2026, the Group's current liabilities exceeded its current assets by RMB85.8 million (as at December 31, 2025: RMB44.4 million). The increase in the Group's net current liabilities was mainly due to capital cash expenditures for the acquisition of medical equipment during the Reporting Period.

Liquidity and Capital Resources

As at June 30, 2026, the Group had cash and cash equivalents of RMB1,065.3 million (as at December 31, 2025: RMB1,135.4 million), with available unused bank facilities of RMB290.0 million (as at December 31, 2025: RMB321.0 million). As at June 30, 2026, the Group had outstanding borrowings of RMB570.0 million (as at December 31, 2025: RMB635.6 million), with non-current portion of long-term borrowings of RMB224.9 million (as at December 31, 2025: RMB242.5 million). Based on the Group's past experience and good credit standing, the Directors are confident that such bank facilities could be renewed or extended for at least 12 months upon maturity. We adopt prudent treasury policies in cash and financial management to achieve better risk control, manage financial resources efficiently and minimize the cost of funds. For the currency in which cash and cash equivalents are denominated, please refer to Note 15 to the interim condensed consolidated financial information. As of June 30, 2026, the Group had not used any financial instruments for hedging purposes.

Significant Investments, Material Acquisitions and Disposals

During the Reporting Period, the Group did not have any significant investment, material acquisition or material disposal.

Future Plans for Material Investments and Capital Asset

Save as disclosed in this report, as of June 30, 2026, the Group did not have detailed future plans for material investments and capital assets.

Capital Expenditure and Commitments

For the Reporting Period, the Group incurred capital expenditures of RMB166.2 million (corresponding period in 2025: RMB175.1 million), primarily for (i) purchases of medical equipment as well as renovation for the Group's medical examination centers; and (ii) the lease of business premises for new medical examination centers.

As at June 30, 2026, the Group had a total capital commitment of RMB19.7 million (as at December 31, 2025: RMB30.4 million), mainly comprising leasehold improvement.

Borrowings
As at June 30, 2026, the Group had total bank and other borrowings of RMB570.0 million (as at December 31, 2025: RMB635.6 million). All the borrowings are denominated in RMB. Please refer to Note 19 to the interim condensed consolidated financial information for more details.

Contingent Liabilities
The Group had no material contingent liability as at June 30, 2026 (as at December 31, 2025: Nil).

Gearing Ratio
As at June 30, 2026, on the basis of net debt divided by total capital, the Group's gearing ratio was 32.9% (as at December 31, 2025: 33.8%).

Cash Flow and Fair Value Interest Rate Risk
Our exposure to changes in interest rates is mainly attributable to our bank borrowings and lease liabilities.

Borrowings obtained at variable rates expose us to cash flow interest rate risk. Borrowings obtained at fixed rates expose us to fair value interest rate risk. As at June 30, 2026, borrowings of RMB570,025,000 were with floating interest rates (as at December 31, 2025: RMB635,600,000). We did not hedge our cash flow and fair value interest rate risk during the Reporting Period.

Foreign Exchange Risk
For the Reporting Period, the Group was not exposed to significant foreign currency risk, except for bank deposits denominated in Hong Kong dollar and United States dollar. The Group currently does not have a foreign currency hedging policy. However, the management closely monitors foreign exchange exposure and will consider hedging significant foreign exchange exposure should the need arise.

Credit Risk
We have no significant concentration of credit risk. The carrying amount of cash and cash equivalents, trade and other receivables and deposits from long-term leases represent our maximum exposure to credit risk in relation to our financial assets. The objective of our measures to manage credit risk is to control potential exposure to recoverability problem.

Cash and cash equivalents were deposited in the major financial institutions, which the directors believe are of high credit quality.

The Group has policies in place to ensure that receivables with credit terms are made to counterparties with an appropriate credit history and the management performs ongoing credit evaluations of the counterparties. The credit period granted to the customers and the credit quality of these customers are assessed, with reference to their financial position, past experience and available forward-looking information. The Group considers the probability of default upon initial recognition of a financial asset and whether there has been a significant increase in credit risk on an ongoing basis throughout each reporting period. The Group also considers available reasonable and supportive forward-looking information.

The credit risk of hospital business is related to the recoverability of trade receivables and other receivables. The credit risk of medical examination business is related to the length of the overdue period of trade receivables from corporate customers and other receivables.

Liquidity Risk

Our finance department monitors rolling forecasts of our liquidity requirements to ensure that we have sufficient cash to meet operational needs while maintaining sufficient headroom on our undrawn borrowing facilities at all times so that we do not breach borrowing limits or covenants (where applicable) on any of our borrowing facilities. We expect to fund the future cash flow needs through cash flows generated from operations, borrowings from financial institutions and issuing debt instruments or capital contribution from the shareholders of the Company (the "**Shareholders**"), as necessary. Based on contractual undiscounted payments, our financial liabilities were RMB2,639.7 million as at June 30, 2026 (as at December 31, 2025: RMB2,772.4 million).

Pledge of Assets

As at June 30, 2026, the Group had assets with a total carrying amount of RMB666,132,000 (as at December 31, 2025: assets of RMB693,350,000) pledged for the Group's borrowings.

HUMAN RESOURCES

The Group had a total of 8,542 (December 31, 2025: 8,523) employees as of June 30, 2026. The employee benefits expenses were approximately RMB552 million for the Reporting Period and RMB469 million for the corresponding period in 2025. The Group enters into employment contracts with its employees to cover matters such as position, term of employment, wage, employee benefits and liabilities for breaches and grounds for termination. Remuneration of the Group's employees includes basic salaries, allowances, bonus, share option scheme and other employee benefits, and is determined with reference to their experience, qualifications and general market conditions. The emolument policy for the employees of the Group is set up by the Board on the basis of their merit, qualification and competence. We provide regular training to our employees in order to improve their skills and knowledge. The training courses range from further educational studies to skill training to professional development courses for management personnel, including a management trainee program.

Supplementary Information

INTERIM DIVIDEND

The Board has resolved not to declare any interim dividend for the Reporting Period (for the six months ended June 30, 2025: Nil).

SUBSEQUENT EVENTS

There has been no other significant event since the end of the Reporting Period and up to the date of this report that is required to be disclosed by the Company.

CORPORATE GOVERNANCE PRACTICES

The Company recognises the importance of good corporate governance for enhancing the management of the Company as well as preserving the interests of the Shareholders as a whole. The Company has adopted the code provisions as set out in the Corporate Governance Code (the "**CG Code**") as contained in Appendix C1 to the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**"), as its own code to govern its corporate governance practices.

In the opinion of the Directors, the Company has complied with the relevant code provisions contained in the CG Code during the Reporting Period, save for deviation from code provisions C.1.7 and C.2.1 of the CG Code.

Code provision C.1.7 of the CG Code provides that appropriate insurance cover in respect of legal action against directors should be arranged. For the Reporting Period, the Company did not have insurance cover for legal action against the Directors. However, pursuant to the Company's articles of association, the Directors shall be indemnified and secured harmless out of the assets and profits of the Company from and against all actions, costs, charges, losses, damages and expenses which they or any of them shall or may incur or sustain by or by reason of any act done, concurred in or omitted in or about the execution of their duty, or supposed duty, in their respective offices. In view of the above, the Board considers that the Directors' exposure to litigation risk is manageable even if there is no insurance cover for legal action against the Directors.

Pursuant to code provision C.2.1 of the CG Code, the responsibility between the chairman and the chief executive officer should be segregated and should not be performed by the same individual. However, the Company does not have a separate chairman and the chief executive officer and Dr. Fang Yixin ("**Dr. Fang**") performs these two roles. The Board considers that vesting the roles of the chairman and the chief executive officer in Dr. Fang is beneficial to the Group for implementing its new business strategies given his abundant experience in the healthcare industry and longtime and substantive involvement in the day to day management and operation of the Group. In addition, the balance of power and authority is ensured by the operation of the Board and the senior management, which comprises experienced and capable individuals independent from Dr. Fang (except his spouse, Dr. Mei Hong, and his son, Mr. Fang Haoze). The Board comprised four executive Directors and three independent non-executive Directors as at the date of this announcement and has a fairly strong independence element in its composition.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding dealings in the securities of the Company by the Directors and the Group's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities.

Upon specific enquiry, all Directors confirmed that they have complied with the Model Code during the Reporting Period. In addition, the Company is not aware of any non-compliance of the Model Code by the senior management of the Group during the Reporting Period.

PROPOSED CHANGE OF AUDITOR

At the last annual general meeting of the Company held on June 17, 2026, BDO Limited ("**BDO**") was re-appointed as the auditor of the Company and to hold office until the conclusion of the next annual general meeting of the Company. However, the Company could not reach a consensus with BDO in respect of the audit fee of the Company for the year ending December 31, 2026.

BDO has resigned as the auditor of the Company on July 27, 2026 (the "**Resignation**") upon passing relevant resolution at an extraordinary general meeting to be convened and held by the Company at 2:00 p.m. on October 12, 2026 (the "**EGM**"). With the recommendation of the Audit Committee, subject to the Resignation becoming effective by way of passing an ordinary resolution at the EGM, the Board resolved to appoint Rongcheng (Hong Kong) CPA Limited (formerly known as CL Partners CPA Limited) as the new auditor of the Company (the "**Proposed Appointment**", together with the Resignation, the "**Proposed Change of Auditor**") to fill the casual vacancy following the resignation of BDO and hold office until the conclusion of the next annual general meeting of the Company. The Proposed Appointment is subject to, among other things, the passing of the relevant resolution at the EGM.

Please refer to (i) the announcement of the Company dated July 27, 2026; (ii) the supplemental announcement of the Company dated August 28, 2026; and (iii) the circular of the Company dated September 21, 2026 for details.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Directors have been granted the general mandate (the "**Repurchase Mandate**") pursuant to resolutions of the Shareholders passed on June 17, 2026, to repurchase shares of the Company in the open market from time to time. Pursuant to the Repurchase Mandate, the Company is allowed to repurchase up to 10% of the total number of issued shares of the Company (excluding treasury shares if any) as at the date of passing such resolution.

From January to June 2026, the Company cumulatively repurchased 1,899,000 shares at the lowest and highest purchase prices of HK$0.66 and HK$0.93 per share, respectively, for a total purchase amount of HK$1,452,890. Such repurchased shares were held as treasury shares. Details of the share repurchases are summarized as follows:

Month of repurchase	Total number of shares repurchased	Repurchased price per share Lowest (HK$)	Repurchased price per share Highest (HK$)	Aggregate consideration (HK$)
May 2026	147,000	0.66	0.71	101,110
June 2026	1,752,000	0.69	0.93	1,351,780

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including treasury shares) during the Reporting Period.

REVIEW OF FINANCIAL INFORMATION

Audit Committee

The audit committee of the Board, comprising Ms. Wong Sze Wing, Mr. Jiang Peixing and Mr. Tian Wenguo, has discussed with the management and reviewed the unaudited interim condensed consolidated financial information of the Group for the Reporting Period.

CHANGES OF MEMBERS OF THE BOARD AND UPDATE ON THE DIRECTORS' INFORMATION PURSUANT TO RULE 13.51B(1) OF THE LISTING RULES

There is no change in information on the Directors since the date of the annual report 2025 of the Company which is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

CONTINUING DISCLOSURE OBLIGATION PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations under Rules 13.20, 13.21 and 13.22 of the Listing Rules.

INTERESTS OF DIRECTORS AND CHIEF EXECUTIVE IN SECURITIES

As at June 30, 2026, the interests or short positions of the Directors and chief executive of the Company in the shares, underlying shares and debentures of the Company and its associated corporations (within the meaning of Part XV of the SFO), which (a) were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she was taken or deemed to have under such provisions of the SFO); or (b) were required, pursuant to section 352 of the SFO, to be recorded in the register referred to therein; or (c) were required to be notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

(A) Long/Short position in ordinary shares of the Company

Name of Director	Long/Short position	Capacity	Number of ordinary shares interested[1]	Approximate percentage+ of the Company's issued share capital
Dr. Mei[2]	Long position	Interest in controlled corporation	971,389,200 (L)	61.08%
Dr. Fang[3]	Long position	Interest of spouse	971,389,200 (L)	61.08%

(B) Long position in underlying shares of the Company — physically settled unlisted equity derivatives

Name of Director	Capacity	Number of underlying shares in respect of the share options granted[1][2]	Approximate percentage+ of the Company's issued share capital
Dr. Mei[2]	Beneficial owner; Interest of spouse	31,807,000 (L)	2.00%
Dr. Fang[3]	Beneficial owner; Interest of spouse	31,807,000 (L)	2.00%

Notes:

(1) The letter "L" denotes the person's long position in the Shares and the letter "S" denotes the person's short position in the Shares.

(2) Chelsea Grace was beneficially interested in the 971,389,200 Shares as at June 30, 2026. Under the SFO, Dr. Mei is deemed to be interested in all the Shares held by Chelsea Grace by reason of her 100% interest in its issued share capital. She is also deemed to be interested in all the interests held by Dr. Fang as she is the wife of Dr. Fang who is granted an option to subscribe for 15,903,500 Shares under the Pre-IPO Share Option Scheme. Dr. Mei is granted an option to subscribe for 15,903,500 Shares under the Pre-IPO Share Option Scheme. Therefore, Dr. Mei is deemed to be interested in a total of 1,003,196,200 Shares, which represents 63.08 % of the issued share capital of the Company as of June 30, 2026.

(3) Dr. Fang is the husband of Dr. Mei. Therefore, Dr. Fang is deemed to be interested in Dr. Mei's interests in our Company who is granted an option to subscribe for 15,903,500 Shares under the Pre-IPO Share Option Scheme. Dr. Fang is granted an option to subscribe for 15,903,500 Shares under the Pre-IPO Share Option Scheme. Therefore, Dr. Fang is deemed to be interested in a total of 1,003,196,200 Shares, which represents 63.08 % of the issued share capital of the Company as of June 30, 2026.

\+ The percentage represents the number of ordinary shares/underlying shares interested divided by the number of the Company's issued shares as at June 30, 2026.

(C) Interest in associated corporation

Name of Director	Associated corporation	Capacity/ nature of interest	Number of shares	Percentage of shareholding interest
Dr. Mei[1]	Chelsea Grace[2]	Beneficial owner	1	100%
Dr. Fang[1]	Chelsea Grace[2]	Interest of spouse	1	100%

Notes:

(1) Dr. Fang is the husband of Dr. Mei. Therefore, under the SFO, Dr. Fang is deemed to be interested in Dr. Mei's interests in Chelsea Grace.

(2) Under the SFO, a holding company of the listed corporation is regarded as an "associated corporation". As at June 30, 2026, Chelsea Grace held 61.08 % of our issued share capital and thus was our associated corporation.

Save as disclosed in this interim report and to the best knowledge of the Directors, as at June 30, 2026, none of the Directors or the chief executive of the Company has any interests and/or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they are taken or deemed to have under such provisions of the SFO) or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS IN SECURITIES

So far as is known to any Director or chief executive of the Company, as at June 30, 2026, the following corporations/persons (other than Directors or the chief executive of the Company) had interests of 5% or more in the issued shares of the Company according to the register of interests required to be kept by the Company under section 336 of the SFO:

Long/Short position in ordinary shares of the Company

Name	Capacity	Number of ordinary shares interested(1)	Approximate percentage+ of the Company's issued share capital
Chelsea Grace	Beneficial owner	971,389,200 (L)	61.08%

Notes:

(1) The letter "L" denotes the person's long position in the Shares and the letter "S" denotes the person's short position in the Shares.

\+ The percentage represents the number of ordinary Shares interested divided by the number of the issued Shares as at June 30, 2026.

Save as disclosed above and to the best knowledge of the Directors, as at June 30, 2026, no person (other than the Directors or chief executives of the Company) had registered an interest or a short position in the Shares or underlying shares of the Company as recorded in the register required to be kept by the Company under section 336 of the SFO.

PRE-IPO SHARE OPTION SCHEME AND SHARE OPTION SCHEME

Pre-IPO Share Option Scheme

The Company conditionally approved and adopted the Pre-IPO Share Option Scheme pursuant to the resolutions of the Shareholders passed on September 19, 2016.

The purpose of the Pre-IPO Share Option Scheme is to attract, retain and motivate employees and Directors, and to provide a means of compensating them through the grant of options for their contribution to the growth and profits of the Group, and to allow such employees and Directors to participate in the growth and profitability of the Group.

Participants of the Pre-IPO Share Option Scheme include (a) any employee (whether full time or part time) of the Company or its subsidiaries, including any executive Director, (b) any non-executive Director or independent non-executive Director of the Company appointed or proposed to be appointed prior to the Listing Date, or any director of any of the subsidiaries, and (c) any other person who in the sole opinion of the Board, will contribute or have contributed to the Group.

A remittance of HK$1.00 by way of consideration for the grant shall be payable at the acceptance of the offer of the grant of options.

The Pre-IPO Share Option Scheme shall remain in full force and effect to the extent necessary to give effect to the exercise of any option granted prior thereto. Options granted thereunder shall be exercisable for a period not be longer than ten years from the date of the grant of the option. The Pre-IPO Share Option Scheme expires on 19 September 2026.

On September 19, 2016, options (exercisable for 10 years from the date of grant subject to vesting schedule as set out below) to subscribe for an aggregate of 47,710,500 Shares were conditionally granted by the Company under the Pre-IPO Share Option Scheme to a total of three grantees, including two executive Directors. Such options were granted based on the performance of the grantees that have made important contributions or are important to the long term growth and profitability of the Group. The exercise price is HK$1.60 per Share as determined by the Board taking into account of the grantees' contribution to the development and growth of the Group. Apart from the above share options, no options were granted under the Pre-IPO Share Option Scheme. In addition, no further options can be granted under the Pre-IPO Share Option Scheme on or after the Listing Date. The total number of Shares underlying the outstanding options granted under the Pre-IPO Share Option Scheme is 47,710,500 Shares, representing approximately 3.0% of the issued share capital of the Company as at the date of this interim report.

Subject to the terms of the Pre-IPO Share Option Scheme, each option shall be vested in the following manner:

Tranche	Vesting Date
five percent (5%) of the Shares subject to an option so granted	third (3rd) anniversary of the offer date for an option
ten percent (10%) of the Shares subject to an option so granted	fourth (4th) anniversary of the offer date for an option
fifteen percent (15%) of the Shares subject to an option so granted	fifth (5th) anniversary of the offer date for an option
seventy percent (70%) of the Shares subject to an option so granted	sixth (6th) anniversary of the offer date for an option

No options were exercised, cancelled or lapsed by the Company under the Pre-IPO Share Options Scheme during the Reporting Period.

Details of movement of the share options granted under the Pre-IPO Share Option Scheme for Reporting Period are set out below:

					Number of options				
Name of option holder	Outstanding as at January 1, 2026	Date of grant	Vesting Period	Exercise Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	Exercise Price
Directors of the Company									
Dr. Fang	15,903,500	September 19, 2016	See above vesting schedule	Exercisable for 10 years from date of grant	–	–	–	15,903,500	HK$1.60
Dr. Mei	15,903,500	September 19, 2016	See above vesting schedule	Exercisable for 10 years from date of grant	–	–	–	15,903,500	HK$1.60
Senior management and other employees of the Group									
Cao Ying	15,903,500	September 19, 2016	See above vesting schedule	Exercisable for 10 years from date of grant	–	–	–	15,903,500	HK$1.60
Total	47,710,500				–	–	–	47,710,500	

The Directors who have been granted options under the Pre-IPO Share Option Scheme, have undertaken that they will not exercise the options granted to them under the Pre-IPO Share Option Scheme if as a result of which the Company would not be able to comply with the public float requirements of the Listing Rules.

A summary of the terms (including the terms of the scheme, the calculation method of the exercise price and vesting periods and conditions) of the Pre-IPO Share Option Scheme has been set out in the section headed "E. Pre-IPO Share Option Scheme" in Appendix IV of the Prospectus.

The Pre-IPO Share Option Scheme does not fall within the ambit of, and is not subject to, the regulations under Chapter 17 of the Listing Rules. Details of the impact of options granted under the Pre-IPO Share Option Scheme on the consolidated financial statements since the date of grant of such options and the subsequent financial periods are set out under Note 18 to the interim consolidated financial statements in this interim report.

Share Option Scheme

On September 19, 2016, the Company adopted the Share Option Scheme, which falls within the ambit of, and is subject to, the regulations under Chapter 17 of the Listing Rules. The purpose of the Share Option Scheme is to attract, retain and motivate employees, Directors and other participants, and to provide a means of compensating them through the grant of options for their contribution to the growth and profits of the Group, and to allow such employees, Directors and other persons to participate in the growth and profitability of the Group.

The participants of the Share Option Scheme include any non-executive Director or independent non-executive Director appointed or proposed to be appointed prior to the Listing Date, or any director of any of the subsidiaries, or any employee (whether full time or part time) of the Company or its subsidiaries, including any executive Director as the Board may in its absolute discretion select.

The Shares which may be issued upon exercise of all Options to be granted under the Share Option Scheme and other share option schemes of our Company (and to which the provisions of the Listing Rules are applicable) shall not exceed 79,517,500 Shares (i.e. 5% of the aggregate of the Shares in issue on the Listing Date) ("**Scheme Mandate Limit**"), representing approximately 5% of the total issued shares as at the date of this interim report. Options lapsed in accordance with the terms of the Share Option Scheme shall not be counted for the purpose of calculating this Scheme Mandate Limit.

The total number of Shares issued and to be issued upon the exercise of the options granted to or to be granted to each eligible person under the Share Option Scheme (including exercised, cancelled and outstanding options) in any 12-month period shall not exceed 1% of the Shares in issue.

The Share Option Scheme will remain in force for a period of 10 years from September 19, 2016 and the options granted have a 10-year exercise period. The Share Option Scheme expires on 19 September 2026. Options may be vested over such period(s) as determined by the Board in its absolute discretion subject to compliance with the requirements under any applicable laws, regulations or rules.

A remittance of HK$1.00 by way of consideration for the grant shall be payable at the acceptance of the offer of the grant of options. The exercise price of the option shall be such price as determined by the Board in its absolute discretion at the time of the grant of the relevant option (and shall be stated in the letter containing the offer of the grant of the option), but in any case the exercise price shall not be less than the higher of (a) the closing price of the Shares as stated in the daily quotation sheet of the Stock Exchange on the date of grant, which must be a business day, (b) the average closing price of the Shares as stated in the daily quotation sheets of the Stock Exchange for the five (5) business days immediately preceding the date of grant, and (c) the nominal value of a Share.

On November 24, 2017, the Company granted share options to certain then Directors and employees of the Company and its subsidiaries to subscribe for a total of 79,517,500 ordinary shares in the share capital of the Company, at the price of HK$2.42 per Share. The closing price of the Shares before the date of grant of such options was HK$2.35 per Share. No further options are available for grant as at January 1, 2026 and June 30, 2026 respectively. As of June 30, 2026, among the Options granted as described above, options in respect of a total of 700,000 Shares were granted to an associate (as defined under the Listing Rules) of a Director and the acceptance letter was signed. Details of such options granted to the associate of a Director are set out as follows:

Director's associate	Position	Number of options granted
Mr. Mei Ye[1]	Deputy General Manager of Medical Examination Business Department	700,000
Total		700,000

Note:

(1) Mr. Mei Ye is an associate of Dr. Mei.

Details of the options granted under the Share Option Scheme and those remained outstanding as of June 30, 2026 are as follows:

				Number of Options						
Name and Class of Grantees	Date of Grant	Vesting Period	Exercise Period	Outstanding as at January 1, 2026	Granted during the Reporting Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	Exercise Price
(1) Associate of Director										
Mr. Mei Ye	November 24, 2017	See below vesting schedule	10-year exercise period	700,000	–	–	–	–	700,000	HK$2.42
(2) Other Employees	November 24, 2017	See below vesting schedule	10-year exercise period	35,060,000	–	–	–	–	35,060,000	HK$2.42
Total				35,760,000	–	–	–	–	35,760,000	

Note:

(1) Mr. Mei Ye is an associate of Dr. Mei.

20% of the options granted will be exercisable from the date falling on the 3rd anniversary of the date of grant of such options; 20% of the options granted will be exercisable from the date falling on the 4th anniversary of the date of grant of such options; 20% of the options granted will be exercisable from the date falling on the 5th anniversary of the date of grant of such options; and the remaining 40% of the options granted will be exercisable from the date falling on the 6th anniversary of the date of grant of such options.

Details of the impact of the options granted under the Share Option Scheme on the consolidated financial statements since the date of grant of such options and the subsequent financial periods are set out under Note 18 to the consolidated financial statements in this annual report.

A summary of the terms of the Share Option Scheme has been set out in the section headed “F. Share Option Scheme” in Appendix IV of the Prospectus.

The number of Shares that may be issued in respect of the options granted under all share schemes of the Company during the Reporting Period divided by the weighted average number of Shares of the relevant class in issue for the Reporting Period was 5.25%.

Interim Condensed Consolidated Balance Sheet

As at 30 June 2026

	Notes	Unaudited 30 June 2026 RMB'000	Audited 31 December 2025 RMB'000
ASSETS			
Non-current assets			
Property and equipment	7	**1,379,944**	1,422,827
Right-of-use assets	8	**1,090,150**	1,148,344
Intangible assets	9	**14,125**	13,461
Investments accounted for using equity method	10	**1,542**	1,872
Financial assets at fair value through other comprehensive income		**178,090**	162,100
Deposits for long-term leases	11	**71,143**	70,403
Deferred tax assets	12	**124,539**	91,332
Prepayments	16	**217,746**	214,602
		3,077,279	3,124,941
Current assets			
Inventories		**26,865**	29,394
Trade receivables	13	**247,400**	286,060
Other receivables	14	**208,304**	230,664
Prepayments	16	**32,177**	27,674
Financial assets at fair value through profit or loss		**28,743**	10,163
Restricted cash	15(b)	**996**	15,994
Cash and cash equivalents	15(a)	**1,065,317**	1,135,425
Deposits in financial institution		**7,958**	18,065
		1,617,760	1,753,439
Total assets		**4,695,039**	4,878,380
EQUITY			
Equity attributable to owners of the Company			
Share capital	17	**1,065**	1,065
Reserves	18	**1,676,464**	1,645,006
		1,677,529	1,646,071
Non-controlling interests		**24,135**	73,738
Total equity		**1,701,664**	1,719,809

Interim Condensed Consolidated Balance Sheet

As at 30 June 2026

	Notes	Unaudited 30 June 2026 RMB'000	Audited 31 December 2025 RMB'000
LIABILITIES			
Non-current liabilities			
Borrowings	19	**224,875**	242,450
Lease liabilities	21	**1,061,927**	1,114,059
Deferred income	20	**3,031**	4,207
		1,289,833	1,360,716
Current liabilities			
Borrowings	19	**345,150**	393,150
Lease liabilities	21	**266,276**	262,449
Contract liabilities	22	**651,719**	608,612
Trade and other payables	23	**402,805**	475,994
Amount due to related parties	32(d)	**984**	—
Income tax payables		**32,869**	54,468
Deferred income	20	**3,739**	3,182
		1,703,542	1,797,855
Total liabilities		**2,993,375**	3,158,571
Total equity and liabilities		**4,695,039**	4,878,380

The notes on pages 35 to 66 are an integral part of the interim condensed consolidated financial information.

Interim Condensed Consolidated Statement of Profit or Loss

For the six months ended 30 June 2026

	Notes	Unaudited Six months ended 30 June 2026 RMB'000	Unaudited 2025 RMB'000
Revenue	24	**1,138,578**	1,144,849
Cost of sales	26	**(741,475)**	(737,259)
Gross profit		**397,103**	407,590
Distribution costs and selling expenses	26	**(190,284)**	(134,471)
Administrative expenses	26	**(105,831)**	(116,740)
(Impairment losses)/reversal of impairment losses on financial assets	26	**1,222**	(2,543)
Other income	25	**23,219**	20,978
Other losses		**(79)**	(5,855)
Change in fair value of financial assets at fair value through profit or loss		**7,122**	—
Operating profit		**132,472**	168,959
Finance costs	27	**(44,866)**	(53,300)
Finance income	27	**1,003**	3,214
Finance costs — net		**(43,863)**	(50,086)
Share of results of investments accounted for using equity method	10	**(330)**	568
Profit before income tax		**88,279**	119,441
Income tax expense	28	**(23,143)**	(39,696)
Profit for the period		**65,136**	79,745
Profit attributable to:			
Owners of the Company		**45,547**	55,941
Non-controlling interests		**19,589**	23,804
		65,136	79,745
Earnings per share for profit attributable to owners of the Company			
— Basic and diluted	29	**RMB0.03**	RMB0.04

The notes on pages 35 to 66 are an integral part of the interim condensed consolidated financial information.

Interim Condensed Consolidated Statement of Other Comprehensive Income

For the six months ended 30 June 2026

	Unaudited	Unaudited
	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Profit for the period	**65,136**	79,745
Other comprehensive income or loss		
Item will not be subsequently reclassified to profit or loss		
— Change in fair value of financial assets at fair value through other comprehensive income	**15,990**	(1,000)
Total comprehensive income for the period	**81,126**	78,745
Total comprehensive income for the period is attributable to:		
Owners of the Company	**61,537**	54,941
Non-controlling interests	**19,589**	23,804
	81,126	78,745

The notes on pages 35 to 66 are an integral part of the interim condensed consolidated financial information.

Interim Condensed Consolidated Statement of Changes in Equity

For the six months ended 30 June 2026

	Attributable to Owners of the Company				
	Share capital RMB'000	Reserves RMB'000 (Note 18)	Sub-total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
Balance at 1 January 2026 (audited)	**1,065**	**1,645,006**	**1,646,071**	**73,738**	**1,719,809**
Profit for the period	**—**	**45,547**	**45,547**	**19,589**	**65,136**
Other comprehensive income	**—**	**15,990**	**15,990**	**—**	**15,990**
Total comprehensive income	**—**	**61,537**	**61,537**	**19,589**	**81,126**
Repurchase of shares	**—**	**(1,268)**	**(1,268)**	**—**	**(1,268)**
Dividend distribution	**—**	**(27,601)**	**(27,601)**	**(73,980)**	**(101,581)**
Transaction with NCI	**—**	**(3,015)**	**(3,015)**	**(2,557)**	**(5,572)**
Capital injection by non-controlling interest	**—**	**1,805**	**1,805**	**7,345**	**9,150**
Balance at 30 June 2026 (unaudited)	**1,065**	**1,676,464**	**1,677,529**	**24,135**	**1,701,664**
Balance at 1 January 2025 (audited)	1,065	1,344,778	1,345,843	29,300	1,375,143
Profit for the period	—	55,941	55,941	23,804	79,745
Other comprehensive income	—	(1,000)	(1,000)	—	(1,000)
Total comprehensive income	—	54,941	54,941	23,804	78,745
Capital contributions by non-controlling interests of a subsidiary	—	—	—	8,700	8,700
Dividend paid to non-controlling interests	—	—	—	(45,695)	(45,695)
Balance at 30 June 2025 (unaudited)	1,065	1,399,719	1,400,784	16,109	1,416,893

The notes on pages 35 to 66 are an integral part of the interim condensed consolidated financial information.

Interim Condensed Consolidated Statement of Cash Flows

For the six months ended 30 June 2026

	Note	Unaudited Six months ended 30 June 2026 RMB'000	Unaudited 2025 RMB'000
Cash flow from operating activities			
Cash generated from operations		**310,534**	337,384
Interest paid		**(42,560)**	(53,239)
Income tax paid		**(77,949)**	(82,734)
Net cash generated from operating activities		**190,025**	201,411
Cash flow from investing activities			
Purchases of property and equipment		**(58,431)**	(52,894)
Purchases of intangible assets		**(2,055)**	(141)
Purchases of financial assets at fair value through profit or loss		**(17,371)**	(100)
Prepayment for purchases of property and equipment		**(3,144)**	—
Proceeds from disposal of financial assets at fair value through profit or loss		**5,913**	—
Proceeds from disposal of property and equipment		**1,486**	9
Interest received		**1,432**	3,214
Consideration receivable received	14(b)	**1,099**	—
Repayment of loans to third parties		**3,000**	
Repayment of/(loans to) non-controlling interests		**20,000**	(70,000)
Release of restricted bank deposits		**15,000**	1,722
Placement of restricted bank deposits		**(2)**	(2,037)
Net cash used in investing activities		**(33,073)**	(120,227)
Cash flows from financing activities			
Capital contributions from non-controlling interests of subsidiaries		**9,150**	8,700
Proceeds from bank borrowings		**140,000**	231,000
Repayments of bank borrowings		**(205,575)**	(257,200)
Repurchase of shares		**(1,268)**	—
Principal elements of lease payments		**(87,476)**	(98,901)
Purchase of non-controlling interests		**(5,572)**	—
Dividend paid to non-controlling interests		**(73,980)**	(45,695)
Net cash used in financing activities		**(224,721)**	(162,096)
Net decrease in cash and cash equivalents		**(67,769)**	(80,912)
Cash and cash equivalents at beginning of the period		**1,135,425**	1,109,817
Exchange loss on cash and cash equivalents		**(2,339)**	(61)
Cash and cash equivalents at end of the period		**1,065,317**	1,028,844

The notes on pages 35 to 66 are an integral part of the interim condensed consolidated financial information.

Notes to the Interim Condensed Consolidated Financial Information

For the six months ended 30 June 2026

1 General information

Rici Healthcare Holdings Limited (the "**Company**") was incorporated in the Cayman Islands as an exempted company with limited liability under the Companies Law (2013 Revision) of the Cayman Islands on 11 July 2014. The address of the Company's registered office is 4th Floor, Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.

The Company, an investment holding company and its subsidiaries (collectively, the "**Group**") are principally engaged in the provision of general hospital services and medical examination services in the People's Republic of China ("**PRC**").

The Company's shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited since 6 October 2016.

The interim condensed consolidated financial information is presented in thousands of Renminbi ("**RMB'000**"), unless otherwise stated, and was approved and authorised for issue by the board of directors (the "**Board**") of the Company on 28 August 2026.

2 Basis of preparation

This interim condensed consolidated financial information for the six months ended 30 June 2026 has been prepared in accordance with HKAS 34 "Interim Financial Reporting", and does not include all the notes of the type normally included in an annual financial statements. The interim condensed consolidated financial information should be read in conjunction with the annual financial statements of the Group for the year ended 31 December 2025, which have been prepared in accordance with HKFRS Accounting Standards and together with any public announcements made by the Company.

Going concern

As at 30 June 2026, the Group's current liabilities exceeded its current assets by RMB85,782,000. Contract liabilities and deferred income included in current liabilities of the Group as at 30 June 2026 amounting to RMB655,458,000 in aggregate are not expected to create cash outflow for the Group. The Group meets its day-to-day working capital requirements depending on cash flows generated from operating activities, bank borrowings and unutilised banking facilities provided by banks in the PRC. Based on the Group's past experience and good credit standing, the directors are confident on future operating cash flows and that the Group's bank financing could be renewed and/or extended for at least another twelve months upon maturity, as and when necessary. The directors therefore are of the opinion that it is appropriate to adopt the going concern basis in preparing the interim condensed consolidated financial information.

For the six months ended 30 June 2026

3 Accounting policies

The accounting policies applied in the preparation of the interim condensed consolidated financial information are consistent with those of the annual financial statements of the Group for the year ended 31 December 2025, as described in those annual financial statements, except for the adoption of amended standards, as set out below.

(a) Amended standards adopted by the Group

- Amendments to HKAS 21 — Lack of Exchangeability

The amended standards listed above did not have any impact on the amounts recognised in prior years and are not expected to materially affect the current or future reporting period.

(b) New and revised standards and interpretations not yet adopted

Certain new and amendments of HKFRS Accounting Standards have been published but are not mandatory for the financial year beginning 1 January 2026 and have not been early adopted by the Group.

		Effective for annual periods beginning on or after
HKFRS 18	Presentation and Disclosure in Financial Statements	1 January 2027
HKFRS 19 and its amendments	Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to Illustrative Examples on HKFRS 7, HKFRS 18, HKAS 1, HKAS 8, HKAS 36 and HKAS 37	Disclosures about Uncertainties in the Financial Statements	1 January 2027
Amendments to HKAS 28	Disclosures about Uncertainties in the Financial Statements	1 January 2027
Amendments to HKAS 21	Fair Value Option for Investments in Associates and Joint Ventures	1 January 2027
HKFRS 20	Regulatory Assets and Regulatory Liabilities	1 January 2029
Amendments to HKFRS 10 and HKAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined

4 Critical accounting estimates and judgements

The preparation of interim condensed consolidated financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing the interim condensed consolidated financial information, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements of the Group for the year ended 31 December 2025.

5 Financial risk management

5.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including currency risk, cash flow and fair value interest rate risk), credit risk and liquidity risk.

The interim condensed consolidated financial information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2025.

There have been no changes in the risk management policies since year end.

5.2 Foreign exchange risk

The Group is engaged in the provision of general hospital services and medical examination services in the PRC with almost all transactions denominated in RMB. In addition, the majority of the Group's assets and liabilities are denominated in RMB. Accordingly, the Group is not exposed to significant foreign currency risk, except for the bank deposits denominated in Hong Kong Dollar ("**HKD**") and United States Dollar ("**USD**").

The Group currently does not have a foreign currency hedging policy. However, management closely monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

At 30 June 2026, if RMB had weakened/strengthened by 5% against the HKD with all other variables held constant, post-tax profit for the period/year would have been RMB1,226,000 (31 December 2025: RMB2,771,000) higher/lower, mainly as a result of foreign exchange gains/losses on translation of cash in bank.

At 30 June 2026, if RMB had weakened/strengthened by 5% against USD with all other variables held constant, post-tax profit for the period/year would have been RMB175,000 (31 December 2025: RMB604,000) higher/lower, mainly as a result of foreign exchange gains/losses on translation of cash in bank.

For the six months ended 30 June 2026

5 Financial risk management (continued)

5.3 Cash flow and fair value interest rate risk

The Group's exposure to changes in interest rates is mainly attributable to its borrowings from banks.

Borrowings obtained at variable rates expose the Group to cash flow interest rate risk. Borrowings obtained at fixed rates expose the Group to fair value interest rate risk. The Group does not hedge its cash flow and fair value interest rate risk. The interest rates and terms of repayments of borrowings are disclosed in Note 19.

As at 30 June 2026 and 31 December 2025, if interest rates had risen/fallen by 50 basis points with all other variables held constant, the Group's net results for the period/year would have changed mainly as a result of higher/lower interest expenses on floating rate borrowings. Details of changes are as follows:

	Unaudited Period ended 30 June 2026 RMB'000	Audited Year ended 31 December 2025 RMB'000
Net results (decrease)/increase		
— risen 50 basis points	**(1,172)**	(3,178)
— fallen 50 basis points	**1,172**	3,178

5.4 Credit risk

The Group's credit risk arises from restricted cash, cash and cash equivalents, trade receivables, other receivables, amounts due from related parties and deposits for long-term leases. The credit risk of hospital segment is from the recoverability of trade receivables and other receivables. The credit risk of medical examination segment is from the length of the overdue period of trade receivables and other receivables by corporate customers. The objective of the Group's measures to manage credit risk is to control potential exposure to recoverability problem.

Cash and cash equivalents and restricted cash were deposited in the major financial institutions, which the directors believe are of high credit quality.

The Group established policies in place to ensure that the Group assesses the credit worthiness and financial strength of its customers as well as considering prior dealing history with the customers and volume of sales. Management makes periodic assessment on the recoverability of trade receivables, other receivables, amounts due from related parties and deposits for long-term leases based on historical payment records, the length of the overdue period, the financial strength of the debtors and whether there are any trade disputes with the debtors.

5 Financial risk management (continued)

5.5 Liquidity risk

Group finance monitors rolling forecasts of the Group's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities. The Group expected to fund the future cash flow needs through internally generated cash flows from operations, borrowings from financial institutions and issuing debt instruments and capital injection from shareholders, as necessary.

The table below analyses the Group's financial liabilities that will be settled on a net basis into relevant maturity grouping based on the remaining period at the balance sheet date to the contractual maturity date. The amounts disclosed in the table below are the contractual undiscounted cash flows.

	Less than 1 year RMB'000	Between 1 and 2 years RMB'000	Between 2 and 5 years RMB'000	More than 5 years RMB'000	Total RMB'000
As at 30 June 2026 (Unaudited)					
Borrowings, including interest	**347,820**	**129,350**	**103,336**	**–**	**580,506**
Lease liabilities	**278,413**	**255,068**	**611,893**	**490,278**	**1,635,652**
Trade and other payables	**402,805**	**–**	**–**	**–**	**402,805**
	1,029,038	**384,418**	**715,229**	**490,278**	**2,618,963**
As at 31 December 2025 (Audited)					
Borrowings, including interest	398,385	125,350	123,711	–	647,446
Lease liabilities	268,873	253,441	594,003	532,670	1,648,987
Trade and other payables	475,994	–	–	–	475,994
	1,143,252	378,791	717,714	532,670	2,772,427

The interest on borrowings is calculated based on borrowings held as at 30 June 2026 and 30 June 2025, respectively. Floating-rate interests are estimated using the current interest rate as at 30 June 2026 and 30 June 2025, respectively.

For the six months ended 30 June 2026

5 Financial risk management (continued)

5.6 Fair value estimation

5.6.1 Fair value hierarchy

To provide an indication about the reliability of the inputs used in determining fair value, the Group classifies its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

The following table presents the Group's financial assets measured and recognised at fair value at 30 June 2026 and 31 December 2025 on a recurring basis:

At 30 June 2026	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Assets (unaudited)				
Financial assets at fair value through profit or loss — Listed equity securities	28,743	–	–	28,743
Financial assets at fair value through other comprehensive income — Unlisted equity securities		–	178,090	178,090
Total	28,743	–	178,090	206,833

At 31 December 2025	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
Assets (Audited)				
Financial assets at fair value through profit or loss — Listed equity securities	10,163	–	–	10,163
Financial assets at fair value through other comprehensive income — Unlisted equity securities	–	–	162,100	162,100
Total	10,163	–	162,100	172,263

As at 30 June 2026, the fair value of financial assets at fair value through profit or loss is approximately equal to their carrying amount. There's no change in level 3 instruments for the six months ended 30 June 2026.

Level 1: The fair value of financial instruments traded in active markets (such as publicly traded derivatives and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

5 Financial risk management (continued)

5.6 Fair value estimation (continued)

5.6.1 Fair value hierarchy (continued)

Level 2: The fair value of financial instruments that are not traded in an active market (for example, over–the–counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities.

The fair value of unlisted equity securities classified as financial assets at fair value through other comprehensive income is determined by the directors of the Company based on the valuation report prepared by the independent valuer with market approach using price to revenue ratio. It is a Level 3 recurring fair value measurement. A reconciliation of the opening and closing fair value balances are provided as below:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Opening balance	**162,100**	169,000
Fair value change during the period/year	**15,990**	(6,900)
Closing balance	**178,090**	162,100

One of the key significant unobservable inputs to determine the fair value of unlisted equity securities classified as financial assets at fair value through other comprehensive income is price to revenue ratio.

A higher price to revenue ratio would result in an increase in the fair value of unlisted equity securities classified as financial assets at fair value through other comprehensive income, and vice versa.

5.6.2 Fair values of other financial instruments

The Group also has a number of financial instruments which are not measured at fair value in the balance sheet. For the majority of these instruments, the fair values are not materially different to their carrying amounts, since the interest receivable/payable is either close to current market rates or the instruments are short-term in nature. Fair value of trade receivables, other receivables, amounts due from related parties, deposits in financial institution, restricted cash, cash and cash equivalents, trade and other payables, borrowings, lease liabilities and amount due to a related party approximates to their carrying amount.

For the six months ended 30 June 2026

6 Segment information

Management has determined the operating segments based on the information reviewed by the chief operating decision-maker ("**CODM**") for the purpose of corporate planning, allocating resources and assessing performance.

Management considers the business from a business perspective, and assesses the performance of the business segment based on segment profit without allocation of administrative expenses, reversal of impairment losses on financial assets, impairment losses on financial assets, interest income, interest expenses, net exchange losses, net exchange gains, other income, other losses, share of result of investments accounted for using equity method and income tax expense.

The amounts provided to management with respect to total assets and total liabilities are measured consistent with that of the financial information. These assets are allocated based on the operations of segments. Certain assets and liabilities related to some subsidiaries with corporate function are not allocated into segments. Elimination of revenue are mainly inter-segment service charges related to general hospital business.

The Group manages its business by two operating segments based on their services, which is consistent with the way in which information is reported internally to the Group's CODM for the purpose of resources allocation and performance assessment. The principal assets employed by the Group are located in the PRC, and accordingly, no geographical segment analysis has been prepared.

(a) General hospital

The business of this segment is in Nantong, a city of Jiangsu Province. Revenue from this segment is derived from general hospital services provided by Nantong Rich Hospital Co., Ltd. ("**Nantong Rich Hospital**") and maternity care services provided by Nantong Advanced Hejia Maternity and Child Nursing Service Co., Ltd., and elderly care services provided by Nantong Rich Meidi Elderly Care Centre Co., Ltd. ("**Nantong Meidi**").

(b) Medical examination centers

The business of this segment is in Shanghai city, Jiangsu Province and other provinces in the PRC. Revenue from this segment is derived from medical examination services.

The following table presents revenue and profit information regarding the Group's operation segments for the six months ended 30 June 2026 and 2025, and the segment assets and liabilities as at 30 June 2026 and 31 December 2025.

Revenue between segments are carried out at arm's length and are eliminated on consolidation. The revenue from external parties is measured in the same way as in the interim condensed consolidated statement of profit or loss.

6 Segment information (continued)

	General Hospital RMB'000	Medical Examination Centers RMB'000	Unallocated RMB'000	Elimination RMB'000	Total RMB'000
For the six months ended 30 June 2026 (unaudited)					
Revenue	219,362	927,552	–	(8,336)	1,138,578
Segment profit/(loss)	31,284	175,862	(327)	–	206,819
Administrative expenses					(105,831)
Reversal of impairment losses on financial assets					1,222
Interest income					1,003
Interest expenses					(42,527)
Net exchange losses					(2,339)
Other income					23,219
Other losses					(79)
Change in fair value of financial assets at fair value through profit or loss					7,122
Share of result of investments accounted for using equity method					(330)
Profit before income tax					88,279
Income tax expense					(23,143)
Profit for the period					65,136

	General Hospital RMB'000	Medical Examination Centers RMB'000	Unallocated RMB'000	Elimination RMB'000	Total RMB'000
As at 30 June 2026 (unaudited)					
Segment assets	1,224,832	4,073,231	950,521	(1,553,545)	4,695,039
Segment liabilities	523,065	2,666,036	370,327	(566,053)	2,993,375
For the six months ended 30 June 2026 (unaudited)					
Other information					
Additions to property and equipment, right-of-use assets and intangible assets	7,156	159,042	–	–	166,198
Depreciation and amortisation	23,667	180,289	50	–	204,006

6 Segment information (continued)

	General Hospital RMB'000	Medical Examination Centers RMB'000	Unallocated RMB'000	Elimination RMB'000	Total RMB'000
For the six months ended 30 June 2025 (unaudited)					
Revenue	234,004	925,129	–	(14,284)	1,144,849
Segment profit/(loss)	33,258	241,539	(1,678)	–	273,119
Administrative expenses					(116,740)
Impairment losses					(2,543)
Interest income					3,214
Interest expenses					(53,239)
Net exchange losses					(61)
Other income					20,978
Other losses					(5,855)
Share of result of investments accounted for using equity method					568
Profit before income tax					119,441
Income tax expense					(39,696)
Profit for the period					79,745

	General Hospital RMB'000	Medical Examination Centers RMB'000	Unallocated RMB'000	Elimination RMB'000	Total RMB'000
As at 30 June 2025 (unaudited)					
Segment assets	1,285,877	4,168,976	1,026,903	(1,764,972)	4,716,784
Segment liabilities	590,167	3,065,492	411,629	(767,397)	3,299,891
For the six months ended 30 June 2025 (unaudited)					
Other information					
Additions to property and equipment, right-of-use assets and intangible assets	13,969	161,118	–	–	175,087
Depreciation and amortisation	24,740	186,646	50	–	211,436

For the six months ended 30 June 2026

7 Property and equipment

	Buildings RMB'000	Medical equipments RMB'000	General equipments RMB'000	Leasehold improvements RMB'000	Others RMB'000	Construction in progress RMB'000	Total RMB'000
As at 1 January 2026 (Audited)							
Cost	934,059	947,900	106,277	887,366	14,151	33,299	2,923,052
Accumulated depreciation	(144,270)	(687,985)	(85,534)	(544,558)	(10,130)	–	(1,472,477)
Accumulated impairment loss	–	–	–	(27,748)	–	–	(27,748)
Net book amount	789,789	259,915	20,743	315,060	4,021	33,299	1,422,827
Six months ended 30 June 2026 (Unaudited)							
Opening net book amount	789,789	259,915	20,743	315,060	4,021	33,299	1,422,827
Additions	1,133	20,508	1,930	5,097	133	29,630	58,431
Transfers	375	2,399	70	28,818	–	(31,662)	–
Disposal	–	(7)	(4)	(1,473)	–	(6)	(1,490)
Depreciation	(10,954)	(43,267)	(2,844)	(42,039)	(720)	–	(99,824)
Closing net book amount	780,343	239,548	19,895	305,463	3,434	31,261	1,379,944
As at 30 June 2026 (Unaudited)							
Cost	935,567	972,349	108,378	920,118	14,284	31,261	2,981,957
Accumulated depreciation	(155,224)	(732,801)	(88,483)	(586,907)	(10,850)	–	(1,574,265)
Accumulated impairment loss	–	–	–	27,748	–	–	27,748
Net book amount	780,343	239,548	19,895	305,463	3,434	31,261	1,379,944
As at 1 January 2025 (Audited)							
Cost	939,066	896,730	102,146	820,840	14,535	30,987	2,804,304
Accumulated depreciation	(122,434)	(611,213)	(78,769)	(466,857)	(9,763)	–	(1,289,036)
Accumulated impairment loss	–	–	–	(23,413)	–	–	(23,413)
Net book amount	816,632	285,517	23,377	330,570	4,772	30,987	1,491,855
Six months ended 30 June 2025 (Unaudited)							
Opening net book amount	816,632	285,517	23,377	330,570	4,772	30,987	1,491,855
Additions	132	7	–	2,636	–	50,119	52,894
Transfers	–	17,079	2,412	15,691	–	(35,212)	(30)
Disposal	(5,140)	(224)	(11)	(553)	–	(175)	(6,103)
Depreciation	(10,937)	(45,271)	(3,924)	(42,260)	(375)	–	(102,767)
Closing net book amount	800,687	257,108	21,854	306,084	4,397	45,719	1,435,849
As at 30 June 2025 (Unaudited)							
Cost	934,058	901,509	103,716	838,662	14,151	45,719	2,837,815
Accumulated depreciation	(133,371)	(644,401)	(81,862)	(509,165)	(9,754)	–	(1,378,553)
Accumulated impairment loss	–	–	–	(23,413)	–	–	(23,413)
Net book amount	800,687	257,108	21,854	306,084	4,397	45,719	1,435,849

7 Property and equipment (continued)

Notes:

(a) Depreciation of property and equipment has been charged to the interim condensed consolidated statement of profit or loss as follows:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Cost of sales	**92,115**	180,452
Distribution costs and selling expenses	**55**	115
Administrative expenses	**7,654**	23,705
	99,824	204,272

(b) As at 30 June 2026, buildings with a total carrying amount of RMB663,584,000 (31 December 2025: RMB690,752,000) were pledged for the Group's borrowings (Note 19).

8 Right-of-use assets

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Properties	**1,087,602**	1,145,746
Land use rights	**2,548**	2,598
	1,090,150	1,148,344

8 Right-of-use assets (continued)

	Properties RMB'000	Land use rights RMB'000	Total RMB'000
As at 1 January 2026 (Audited)			
Cost	**1,991,009**	**4,698**	**1,995,707**
Accumulated depreciation	**(845,263)**	**(2,100)**	**(847,363)**
Net book amount	**1,145,746**	**2,598**	**1,148,344**
Opening net book amount	**1,145,746**	**2,598**	**1,148,344**
Additions	**105,712**	**—**	**105,712**
Modification	**(30,664)**	**—**	**(30,664)**
Termination	**(30,451)**	**—**	**(30,451)**
Depreciation	**(102,741)**	**(50)**	**(102,791)**
Closing net book amount	**1,087,602**	**2,548**	**1,090,150**
As at 30 June 2026 (Unaudited)			
Cost	**1,979,112**	**4,698**	**1,983,810**
Accumulated depreciation	**(891,510)**	**(2,150)**	**(893,660)**
Net book amount	**1,087,602**	**2,548**	**1,090,150**
As at 1 January 2025 (Audited)			
Cost	1,976,479	4,698	1,981,177
Accumulated depreciation	(681,630)	(2,000)	(683,630)
Net book amount	1,294,849	2,698	1,297,547
Six months ended 30 June 2025 (Unaudited)			
Opening net book amount	1,294,849	2,698	1,297,547
Additions	122,052	—	122,052
Revaluation	(22,539)	—	(22,539)
Disposals	(29,029)	—	(29,029)
Depreciation	(107,163)	(50)	(107,213)
Closing net book amount	1,258,170	2,648	1,260,818
As at 30 June 2025 (Unaudited)			
Cost	2,033,489	4,698	2,038,187
Accumulated depreciation	(775,319)	(2,050)	(777,369)
Net book amount	1,258,170	2,648	1,260,818

As at 30 June 2026, land with a total carrying amount of RMB2,548,000 (31 December 2025: RMB2,598,000) were pledged for the Group's borrowings (Note 19).

For the six months ended 30 June 2026

9 Intangible assets

	Computer software RMB'000	Goodwill RMB'000	Total RMB'000
As at 1 January 2026 (Audited)			
Cost	**48,924**	**—**	**48,924**
Accumulated amortisation	**(35,463)**	**—**	**(35,463)**
Accumulated impairment	**—**	**—**	**—**
Net book amount	**13,461**	**—**	**13,461**
Six months ended 30 June 2026 (Unaudited)			
Opening net book amount	**13,461**	**—**	**13,461**
Addition	**2,055**	**—**	**2,055**
Transfer from construction in progress	**—**	**—**	**—**
Amortisation	**(1,391)**	**—**	**(1,391)**
Closing net book amount	**14,125**	**—**	**14,125**
As at 30 June 2026 (Unaudited)			
Cost	**50,979**	**—**	**50,979**
Accumulated amortisation	**(36,854)**	**—**	**(36,854)**
Accumulated impairment	**—**	**—**	**—**
Net book amount	**14,125**	**—**	**14,125**
As at 1 January 2025 (Audited)			
Cost	48,253	7,447	55,700
Accumulated amortisation	(32,617)	—	(32,617)
Accumulated impairment	—	(7,447)	(7,447)
Net book amount	15,636	—	15,636
Six months ended 30 June 2025 (Unaudited)			
Opening net book amount	15,636	—	15,636
Addition	141	—	141
Transfer from construction in progress	30	—	30
Amortisation	(1,456)	—	(1,456)
Closing net book amount	14,351	—	14,351
As at 30 June 2025 (Unaudited)			
Cost	48,423	7,447	55,870
Accumulated amortization	(34,072)	—	(34,072)
Accumulated impairment	—	(7,447)	(7,447)
Net book amount	14,351	—	14,351

For the six months ended 30 June 2026

10 Investments accounted for using equity method

	Unaudited	Unaudited
	Six months ended 30 June	
	2026	2025
	RMB'000	RMB'000
Opening balance	**1,872**	10,485
Share of results	**(330)**	568
Ending balance	**1,542**	11,053

The particulars of the joint venture and associate of the Group during the periods, which are unlisted, are set out as follows:

			Equity interests held		
Company name	Date/location of incorporation and operation	Paid-in capital	As at 30 June 2026	As at 31 December 2025	Principal activities
Neijiang Rich Ruichuan Clinic Co., Ltd.	29 March 2017, Sichuan, the PRC	RMB14,313,000	**20%**	20%	Examination service

11 Deposits for long-term leases

The Group paid deposits for leases of certain medical examination centers, which are due over 1 year from balance sheet date and are recoverable at the end of the lease term.

For the six months ended 30 June 2026

12 Deferred tax assets

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
The balance comprises temporary differences attributable to:		
Tax losses	**52,704**	19,055
Right-of-use assets and lease liabilities	**46,602**	46,285
	99,306	65,340
Share option scheme	**21,882**	21,882
Loss allowances for financial assets	**2,511**	3,269
Impairment of property and equipment	**840**	841
	25,233	25,992
Total deferred tax assets	**124,539**	91,332

Movements in deferred income tax assets for both six months ended 30 June 2026 and 2025, without taking into consideration the offsetting of balance within the same tax jurisdiction, are as follows:

	Tax losses carried forward RMB'000	**Right-of-use assets and lease liabilities** RMB'000	**Share option scheme** RMB'000	**Assets impairment** RMB'000	**Total** RMB'000
As at 1 January 2026 (audited)	**19,055**	**46,285**	**21,882**	**4,110**	**91,332**
Credited/(debited) to condensed consolidated statement of profit or loss	**33,649**	**317**	**—**	**(759)**	**33,207**
As at 30 June 2026 (unaudited)	**52,704**	**46,602**	**21,882**	**3,351**	**124,539**
As at 1 January 2025 (audited)	37,005	45,401	24,279	11,551	118,236
Credited/(debited) to condensed consolidated statement of profit or loss	29,881	2,393	(2,397)	(4,478)	25,399
As at 30 June 2025 (unaudited)	66,886	47,794	21,882	7,073	143,635

Deferred income tax assets are recognised for tax loss carry-forwards to the extent that the realization of the related tax benefit through future taxable profits is probable. The Group did not recognise deferred income tax assets of RMB93,752,000 (31 December 2025: RMB96,734,000) in respect of tax losses amounting to RMB376,707,000 (31 December 2025: RMB386,938,000) as at 30 June 2026. All these tax losses will expire within five years.

13 Trade receivables

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Trade receivables	**260,087**	299,328
Less: Loss allowance	**(12,687)**	(13,268)
	247,400	286,060

As at 30 June 2026 and 31 December 2025, the fair value of trade receivables of the Group approximated to their carrying amount.

The aging analysis of trade receivables based on the date the relevant service was rendered is as follows:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Trade receivables		
— Up to 6 months	**236,379**	285,448
— 6 months to 1 year	**18,232**	6,888
— 1 to 2 years	**2,969**	4,405
— 2 to 3 years	**462**	802
— Over 3 years	**2,045**	1,785
	260,087	299,328

Movements of loss allowance for trade receivables are as follows:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
At the beginning of the period/year	**13,268**	33,200
Decrease in loss allowance	**(581)**	(1,989)
Receivables written off as uncollectible	**—**	(17,943)
At the end of the period/year	**12,687**	13,268

For the six months ended 30 June 2026

14 Other receivables

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Loans to non-controlling interests of subsidiaries (Note (a))	**148,000**	168,000
Deposits	**6,632**	6,592
Advances to staff	**5,020**	13,150
Interest receivable	**10,314**	8,070
Others (Note (b))	**40,088**	36,602
	210,054	232,414
Less: Loss allowance	**(1,750)**	(1,750)
	208,304	230,664

Notes:

(a) Balance represents loans to the non-controlling interests of subsidiaries, which are unsecured and bore the interest rate at 1-year loan prime rate plus 1 basis point. They were recoverable within twelve months from the reporting date as at 30 June 2026.

(b) Consideration receivable arising from the disposal of Shanghai Shuixian Obstetrics, Gynecology & Pediatric Hospital Co., Ltd. ("**Rici Shuixian**") during the year ended 31 December 2022 amounted to RMB1,099,000 as at 31 December 2025 and is included in Others. The consideration receivable is unsecured and non-interest bearing. RMB1,099,000 has been received during the period ended 30 June 2026.

The carrying amounts of the Group's other receivables are denominated in RMB.

As at 30 June 2026 and 31 December 2025, the fair value of other receivables approximated to their carrying amount.

For the six months ended 30 June 2026

15 Cash and bank balances

(a) Cash and cash equivalents

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Cash at bank and on hand		
— Denominated in RMB	**1,022,816**	1,085,609
— Denominated in USD	**23,735**	42,774
— Denominated in HKD	**18,766**	7,042
	1,065,317	1,135,425

(b) Restricted cash

The amount of RMB996,000 is a security deposit for the letter of guarantee from the banks (31 December 2025: RMB15,994,000) for the daily operation of the Group as at 30 June 2026.

16 Prepayments

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Non-current:		
Deposit for purchase of investment property	**198,951**	198,951
Prepayments for property and equipment	**18,795**	15,651
	217,746	214,602
Current:		
Prepayments for consumables	**28,586**	13,014
Others (Note)	**3,591**	14,660
	32,177	27,674
Total prepayments	**249,923**	242,276

Note:

Others mainly included prepaid advertising expenses and prepaid property management fee.

For the six months ended 30 June 2026

17 Share capital

Ordinary shares, issued and fully paid:

	Number of ordinary shares	Share capital RMB'000
As at 30 June 2026 (unaudited) and 31 December 2025 (audited)	1,590,324,000	1,065

18 Reserves

	Treasury Shares RMB'000	Share premium RMB'000	Merger and capital reserves RMB'000	Statutory reserves and other reserves RMB'000 (Note a)	FVOCI reserve RMB'000	Share option scheme RMB'000 (Note b)	Retained earnings RMB'000	Total RMB'000
As at 1 January 2026 (audited)	–	462,065	(333,180)	683,160	(17,900)	88,073	762,788	1,645,006
Profit for the period	–	–	–	–	–	–	45,547	45,547
Other comprehensive income	–	–	–	–	15,990	–	–	15,990
Appropriation to statutory reserves	–	–	–	8,434	–	–	(8,434)	–
Dividend distribution	–	(27,601)	–	–	–	–	–	(27,601)
Capital injection by non-controlling interest ("**NCI**")	–	1,805	–	–	–	–	–	1,805
Transaction with NCI	–	(3,015)	–	–	–	–	–	(3,015)
Repurchase of shares	(1,268)	–	–	–	–	–	–	(1,268)
As at 30 June 2026 (unaudited)	(1,268)	433,254	(333,180)	691,594	(1,910)	88,073	799,901	1,676,464
As at 1 January 2025 (audited)	–	462,065	(333,180)	411,040	(11,000)	97,662	718,191	1,344,778
Profit for the period	–	–	–	–	–	–	55,941	55,941
Other comprehensive income	–	–	–	–	(1,000)	–	–	(1,000)
Appropriation to statutory reserves	–	–	–	24,088	–	–	(24,088)	–
Share option scheme	–	–	–	–	–	(9,629)	9,629	–
As at 30 June 2025 (unaudited)	–	462,065	(333,180)	435,128	(12,000)	88,033	759,673	1,399,719

18 Reserves (continued)

Notes:

(a) Statutory reserves and other reserves included the retained earnings of Nantong Rich Hospital as at 30 June 2014 amounted to RMB138,950,000 when Nantong Rich Hospital ceased to be a "not-for-profit medical organization". It is non-distributable and shall be used for the hospital's future development according to the requirements of local authorities.

(b) Share option scheme

The Group approved and launched a share option scheme on 19 September 2016. Pursuant to the share option scheme, two directors and one employee were granted the share options to subscribe for up to 47,710,500 shares of the Company. The share options will vest in four tranches at the third, the fourth, the fifth and the sixth anniversaries of the offer date and will only become exercisable from the respective vesting dates up to the tenth anniversary of the offer date. The subscription price payable upon the exercise of any share option is fixed at HKD1.60.

As at 30 June 2026, 47,710,500 (31 December 2025: 47,710,500) outstanding options were not exercised, among which all options have been vested. These options with an exercise price of HKD1.60 per share upon vesting expire on 19 September 2026.

Another share option scheme was conditionally approved and adopted pursuant to a resolution of the shareholders of the Company passed on 19 September 2016. On and subject to the terms of the share option scheme, the Board shall be entitled at any time within ten years after 19 September 2016 to offer to grant to any non-executive director or independent non-executive director of the Company or any eligible employees of the Company as the Board may in its absolute discretion select, and subject to such conditions as the Board may think fit, an option to subscribe for such number of shares as the Board may determine at the subscription price. One director and ten employees were granted the share options to subscribe for up to 79,517,500 shares of the Company on 24 November 2017. The share options will vest in four tranches at the third, the fourth, the fifth and the sixth anniversaries of the offer date and will only become exercisable from the respective vesting dates up to the tenth anniversary of the offer date. The subscription price payable upon the exercise of the share options is fixed at HKD2.42.

As at 30 June 2026, 35,760,000 (31 December 2025: 35,760,000) outstanding options were not exercised, among which all options have been vested. These options with an exercise price of HKD2.42 per share upon vesting will be expired on 24 November 2027.

The number and weighted average exercise prices of share options are as follows:

	As at 30 June 2026 (Unaudited)		As at 31 December 2025 (Audited)	
	Weighted average exercise price HK$	**Number**	Weighted average exercise price HK$	Number
Outstanding at beginning of the period/year	**1.95**	**83,470,500**	1.95	83,470,500
Forfeited during the period/year	**—**	**—**	—	—
Outstanding at end of the period/year	**1.95**	**83,470,500**	1.95	83,470,500
Exercisable at end of the period/year	**1.95**	**83,470,500**	1.95	83,470,500

For the six months ended 30 June 2026

19 Borrowings

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Bank borrowings — secured and/or guaranteed	**570,025**	635,600
Less: Non-current portion of non-current borrowings	**(224,875)**	(242,450)
	345,150	393,150

The Group's borrowings were repayable as follows:

	Within 1 year RMB'000	**Between 1 and 2 years** RMB'000	**Between 2 and 5 years** RMB'000	**Total** RMB'000
30 June 2026 (Unaudited)				
Bank borrowings	**345,150**	**124,750**	**100,125**	**570,025**
31 December 2025 (Audited)				
Bank borrowings	393,150	121,950	120,500	635,600

As at 30 June 2026, bank borrowings include RMB230,400,000 (31 December 2025: RMB279,600,000) borrowings secured by the Group's land use rights with net book value of RMB2,548,000 (31 December 2025: RMB2,598,000) (Note 8) as at 30 June 2026 and buildings with net book value of RMB663,584,000 (31 December 2025: RMB690,752,000).

All the short-term and long-term bank borrowings are also guaranteed by the Company's subsidiaries for each other.

All the borrowings are denominated in RMB and their fair value approximated to their carrying amounts.

For the six months ended 30 June 2026

20 Deferred income

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
At the beginning of the period/year	**7,389**	10,830
Additions	**983**	441
Transfer to profit or loss	**(1,602)**	(3,882)
	6,770	7,389
Current	**3,739**	3,182
Non-current	**3,031**	4,207
	6,770	7,389

21 Lease liabilities

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Present value of the minimum lease payments:		
Within 1 year	**266,276**	262,449
After 1 year but within 2 years	**221,835**	235,768
After 2 years but within 5 years	**495,684**	497,107
After 5 years	**344,408**	381,184
	1,328,203	1,376,508

For the six months ended 30 June 2026

22 Contract liabilities

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Sales of medical examination cards	**586,136**	588,824
Advances from medical examination customers	**52,064**	10,606
Advances from hospital patients	**13,519**	9,182
	651,719	608,612

Sales of medical examination cards represent the prepayments received from patients and customers and will be recognised in profit or loss when medical examination services are rendered to the relevant customers.

Revenue will be recognised when the relevant services are rendered to the customers. The amount of revenue recognised for the period ended 30 June 2026 that was included in the contract liabilities as at 31 December 2025 was RMB126,918,000 (31 December 2025: RMB174,055,000).

Contract liabilities as at 30 June 2026 are expected to be recognised as revenue in the following one to two years (31 December 2025: one to two years).

23 Trade and other payables

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Trade payables due to third parties	**144,512**	155,462
Payables for purchase of property and equipment	**54,070**	79,811
Staff salaries and welfare payables	**67,509**	108,227
Deposits received	**26,491**	26,246
Accrued taxes other than income tax	**4,721**	6,651
Accrued professional service fees	**2,021**	3,206
Interest payables	**435**	468
Dividend payables	**27,601**	—
Accrued advertising expenses	**391**	357
Others	**75,054**	95,566
	402,805	475,994

23 Trade and other payables (continued)

The aging analysis of the trade payables based on invoice date is as follows:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Trade payables		
— Up to 3 months	**109,754**	133,395
— 3 to 6 months	**14,353**	4,207
— 6 months to 1 year	**4,543**	3,324
— 1 to 2 years	**3,659**	2,161
— 2 to 3 years	**4,121**	3,492
— Over 3 years	**8,082**	8,883
	144,512	155,462

The trade payables are usually paid within 30–60 days of recognition.

The fair value of all trade and other payables of the Group approximated to their carrying amounts and the carrying amounts of the Group's trade and other payables are denominated in RMB.

24 Revenue

Revenue of the Group consists of the following:

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
General hospital		
Inpatient service revenue	**115,065**	107,533
Inpatient pharmaceutical revenue	**43,666**	62,365
Outpatient service revenue	**30,630**	27,988
Outpatient pharmaceutical revenue	**21,665**	21,834
Medical examination centers		
Examination service revenue	**927,371**	924,923
Management service revenue and others	**181**	206
	1,138,578	1,144,849

For the six months ended 30 June 2026

25 Other income

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Government grants (Note)	**17,774**	9,459
Interest income from loans to third parties	**429**	1,487
Others	**5,016**	10,032
	23,219	20,978

Note:

Government grants mainly represent (a) RMB1,602,000 (2025: RMB1,809,900) amortisation of deferred income from the special government grants from Nantong Finance Bureau; (b) subsidies from the People's Government of Beicai Town, Pudong New Area, Shanghai of RMB10,500,000 (2025: nil) during the period ended 30 June 2026; (c) subsidies from Nantong Economic and Technological Development Zone Bureau of Social Affairs of RMB4,580,000 (2025: nil) during the period ended 30 June 2026; and (d) the other government grants in total of RMB1,092,000 during the period ended 30 June 2026 (2025: nil).

26 Expenses by nature

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Employee benefits expenses	**551,574**	469,101
Depreciation and amortization	**204,006**	211,436
Pharmaceutical costs	**38,546**	55,549
Medical consumables costs	**59,397**	51,788
Outsourcing testing expenses	**40,486**	49,140
Utility expenses	**49,609**	45,512
Office expenses	**6,693**	14,867
Maintenance expenses	**11,997**	18,046
Short-term or low-value operating lease rentals	**5,558**	5,517
Platform service charges	**29,267**	29,612
Professional service charges	**6,030**	5,169
Entertainment expenses	**2,753**	6,242
Stamp duty and other taxes	**4,715**	4,500
Advertising expenses	**12,849**	11,505
Labour union dues	**1,123**	1,298
Travel expenses	**3,744**	2,174
(Reversal of impairment losses)/impairment losses on financial assets	**(1,222)**	2,543
Auditor's remuneration	**400**	570
Other expenses	**8,843**	6,444
	1,036,368	991,013

For the six months ended 30 June 2026

27 Finance costs — net

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Interest on lease liabilities	**34,184**	42,168
Interest on borrowings	**8,343**	11,071
	42,527	53,239
Net exchange losses	**2,339**	61
Finance costs	**44,866**	53,300
Interest income	**(1,003)**	(3,214)
Finance income	**(1,003)**	(3,214)
Finance costs — net	**43,863**	50,086

28 Income tax expense

The amount of income tax expense recognised in the interim condensed consolidated statement of profit or loss represents:

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Current income tax		
— Current period	**40,825**	46,692
— Under-provision in respect of prior years	**15,525**	18,403
Deferred income tax (Note 12)	**(33,207)**	(25,399)
Income tax expense	**23,143**	39,696

28 Income tax expense (continued)

The income tax on the Group's profit before income tax differs from the theoretical amount that would arise using the enacted tax rate of the home country of the companies within the Group as follows:

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Profit before income tax	**88,279**	119,441
Tax calculated at the applicable income tax rate (25%)	**22,070**	29,860
Tax effect of:		
Expenses not deductible for tax purpose	**3,373**	1,825
Utilization of tax losses and temporary differences not recognised as deferred tax assets in prior years	**(16,428)**	(6,154)
Temporary differences not recognised as deferred tax assets	**(9,759)**	(5,283)
Tax losses not recognised as deferred tax assets	**9,022**	2,037
Different tax rates of a subsidiary	**(660)**	(992)
Under-provision in respect of prior years	**15,525**	18,403
Income tax expense	**23,143**	39,696

The corporate income tax rate applicable to the Group's subsidiaries located in mainland China is 25%. During the six months ended 30 June 2026, the corporate income tax rate applicable to some of the subsidiaries in mainland China is 15%.

The Company is registered in the Cayman Islands and hence is not subject to corporate income tax. Two subsidiaries in the Group registered in the British Virgin Islands are not subject to corporate income tax.

No provision for Hong Kong profits tax has been made as the Group does not have assessable profits subject to Hong Kong profits tax during the six months ended 30 June 2026 and 2025.

The PRC corporate income tax law and its implementation rules impose a withholding tax at 10% for dividends distributed by a PRC-resident enterprise to its immediate holding company outside the PRC for earnings generated beginning 1 January 2008 and undistributed earnings generated prior to 1 January 2008 are exempted from such withholding tax. A lower 5% withholding tax rate may be applied when the immediate holding companies are established in Hong Kong according to the tax treaty arrangement between the PRC and Hong Kong.

29 Earnings per share

(a) Basic

Basic earnings per share is calculated by dividing the profit attributable to owners of Company by the weighted average number of ordinary shares in issue during the six months ended 30 June 2026 and 2025, respectively.

	Unaudited Six months ended 30 June 2026	2025
Profit attributable to owners of the Company (RMB'000)	**45,547**	55,941
Weighted average number of ordinary shares in issue	**1,590,124,475**	1,590,324,000
Basic earnings per share (RMB)	**0.03**	0.04

(b) Diluted

Diluted earnings per share is calculated by adjusting the weighted number of ordinary shares in issue for the potential dilutive effect caused by the share options granted under the share option scheme assuming they were exercised.

For the six months ended 30 June 2026 and 2025, as the average market share price of the Company's share was lower than assumed exercise price including the fair value of any services to be supplied to the Group in the future under the share option arrangement, there would be no dilutive impact.

30 Contingencies

As at 30 June 2026, the Group had eleven (31 December 2025: eleven) ongoing medical disputes arising from the operation of Nantong Rich Hospital and several disputes arising from medical examination centers which have not been settled. The Group has assessed the individual cases and taken into account of the expenses incurred and recorded, the Group believes the financial exposure in relation to the ongoing disputes shall not be material and thus no additional provision was made in this respect.

For the six months ended 30 June 2026

31 Commitments

Capital commitments

Capital expenditure contracted for but not yet incurred at each balance sheet date, is as follows:

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Authorized and contracted for:		
Leasehold improvement	**19,511**	30,281
Nantong Rich Hospital Renovation	**190**	—
Nantong Rich Hospital Expansion I	**—**	140
	19,701	30,421

32 Related party transactions

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party, has joint control over the other party or exercise significant influence over the other party in making financial and operation decisions. Parties are also considered to be related if they are subject to common control.

The ultimate controlling shareholders of the Group are Dr. Fang and Dr. Mei.

The following is a summary of the significant transactions carried out between the Group and its related parties in the ordinary course of business during the six months ended 30 June 2026 and 2025 and balances arising from related party transactions as at 30 June 2026 and 31 December 2025.

(a) Name and relationship with related parties

Name of related party	Relationship with the Group
Dr. Fang Yixin (方宜新)	Controlling shareholder
Dr. Mei Hong (梅紅)	Controlling shareholder
Nantong Rich Real Estate Development Co., Ltd. (南通瑞慈房地產開發有限公司) ("**Nantong Rici Real Estate**")	Controlled by Dr. Fang
Shanghai Rich Healthcare Management Co., Ltd. (上海瑞慈健康管理有限公司) ("**Shanghai Rich Medical Exam**")	Controlled by Dr. Fang

32 Related party transactions (continued)

(b) Saved as elsewhere disclosed in this financial information, the following transactions were carried out with related parties:

(i) **Expenses paid on behalf of related parties by the Group**

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Nantong Meidi	–	329

(ii) **Services provided to related parties**

	Unaudited Six months ended 30 June 2026 RMB'000	2025 RMB'000
Nantong Meidi	–	786

(iii) **Services and products provided by related parties**

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Shanghai Rich Medical Exam	960	960
Nantong Meidi	–	261
Nantong Rici Real Estate	7	35
	967	1,256

(iv) **Guarantee provided by related parties for borrowings of the Group**

	Unaudited As at 30 June 2026 RMB'000	Audited As at 31 December 2025 RMB'000
Dr. Fang and Dr. Mei	116,025	117,600

32 Related party transactions (continued)

(c) Key management compensation

Key management includes executive directors and non-executive directors. The compensation paid or payable to key management for employee services is shown below:

	Unaudited Six months ended 30 June **2026** **RMB'000**	 2025 RMB'000
Salaries and other short-term employee benefits	**1,607**	1,632
Pension	**107**	125
	1,714	1,757

(d) Balances with related parties

Amount due to a related party

	Unaudited **As at** **30 June 2026** **RMB'000**	Audited As at 31 December 2025 RMB'000
Shanghai Rich Medical Exam	**960**	—
Nantong Rich Real Estate	**24**	16
	984	16

33 Dividend

On 17 June 2026, the shareholders of the Company at the annual general meeting approved the final dividend of HK$0.02 per share for the year ended 31 December 2025, in the aggregate amount of approximately HK$31,806,000. The Board has resolved not to declare any interim dividend for the six months ended 30 June 2026.

瑞慈醫療服務控股有限公司
RICI HEALTHCARE HOLDINGS LIMITED

股份代號 Stock Code: 1526

於開曼群島註冊成立之有限公司 Incorporated in the Cayman Islands with limited liability